

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau




(43) International Publication Date  
29 January 2004 (29.01.2004)

PCT

(10) International Publication Number  
**WO 2004/009769 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N**
- (21) International Application Number:  
PCT/US2003/022444
- (22) International Filing Date: 18 July 2003 (18.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/398,417 24 July 2002 (24.07.2002) US  
10/294,228 14 November 2002 (14.11.2002) US
- (71) Applicant (for all designated States except US): **THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA** [US/US]; Suite 200, 3160 Chestnut Street, Philadelphia, PA 19104-6283 (US).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): **TOLENTINO, Michael, J.** [US/US]; 474 South Ithan avenue, Villanova, PA 19085 (US). **REICH, Samuel, Jotham** [US/US]; 312 Kent Road, Bala Cynwyd, PA 19004 (US).
- (74) Agents: **FRANK, George, A.** et al.; Drinker Biddle & Reath LLP, One Logan Square, 18th and Cherry Streets, Philadelphia, PA 19103-6996 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS



(57) Abstract: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.

WO 2004/009769 A2

## COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS

### 5                    Cross Reference to Related Application

This application claims the benefit of U.S. provisional patent application serial no. 60/398,417, filed on July 24, 2002, and U.S. nonprovisional patent application serial no. 10/294,228, filed November 14, 2002.

10

### Reference to Government Grant

The invention described herein was supported in part by NIH/NEI grant no. R01-EY10820, EY-13410 and EY12156. The U.S. government has certain rights  
15    in this invention.

### Field of the Invention

This invention relates to the regulation of gene expression by small  
20    interfering RNA, in particular for treating diseases or conditions involving angiogenesis.

### Background of the Invention

25            Angiogenesis, defined as the growth of new capillary blood vessels or "neovascularization," plays a fundamental role in growth and development. In mature humans, the ability to initiate angiogenesis is present in all tissues, but is held under strict control. A key regulator of angiogenesis is vascular endothelial growth factor ("VEGF"), also called vascular permeability factor ("VPF"). VEGF  
30    exists in at least four different alternative splice forms in humans (VEGF<sub>121</sub>, VEGF<sub>165</sub>, VEGF<sub>189</sub> and VEGF<sub>206</sub>), all of which exert similar biological activities.

Angiogenesis is initiated when secreted VEGF binds to the Flt-1 and Flk-1/KDR receptors (also called VEGF receptor 1 and VEGF receptor 2), which are expressed on the surface of endothelial cells. Flt-1 and Flk-1/KDR are  
35    transmembrane protein tyrosine kinases, and binding of VEGF initiates a cell

signal cascade resulting in the ultimate neovascularization in the surrounding tissue.

Aberrant angiogenesis, or the pathogenic growth of new blood vessels, is implicated in a number of conditions. Among these conditions are diabetic  
5 retinopathy, psoriasis, exudative or "wet" age-related macular degeneration ("ARMD"), rheumatoid arthritis and other inflammatory diseases, and most cancers. The diseased tissues or tumors associated with these conditions express abnormally high levels of VEGF, and show a high degree of vascularization or vascular permeability.

10 ARMD in particular is a clinically important angiogenic disease. This condition is characterized by choroidal neovascularization in one or both eyes in aging individuals, and is the major cause of blindness in industrialized countries.

A number of therapeutic strategies exist for inhibiting aberrant angiogenesis, which attempt to reduce the production or effect of VEGF. For  
15 example, anti-VEGF or anti-VEGF receptor antibodies (Kim ES et al. (2002), *PNAS USA* 99: 11399-11404), and soluble VEGF "traps" which compete with endothelial cell receptors for VEGF binding (Holash J et al. (2002), *PNAS USA* 99: 11393-11398) have been developed. Classical VEGF "antisense" or aptamer therapies directed against VEGF gene expression have also been proposed (U.S.  
20 published application 2001/0021772 of Uhlmann et al.). However, the anti-angiogenic agents used in these therapies can produce only a stoichiometric reduction in VEGF or VEGF receptor, and the agents are typically overwhelmed by the abnormally high production of VEGF by the diseased tissue. The results achieved with available anti-angiogenic therapies have therefore been  
25 unsatisfactory.

RNA interference (hereinafter "RNAi") is a method of post-transcriptional gene regulation that is conserved throughout many eukaryotic organisms. RNAi is induced by short (*i.e.*, <30 nucleotide) double stranded RNA ("dsRNA") molecules which are present in the cell (Fire A et al. (1998), *Nature* 391: 806-811). These  
30 short dsRNA molecules, called "short interfering RNA" or "siRNA," cause the destruction of messenger RNAs ("mRNAs") which share sequence homology with the siRNA to within one nucleotide resolution (Elbashir SM et al. (2001), *Genes*

*Dev*, 15: 188-200). It is believed that the siRNA and the targeted mRNA bind to an "RNA-induced silencing complex" or "RISC", which cleaves the targeted mRNA. The siRNA is apparently recycled much like a multiple-turnover enzyme, with 1 siRNA molecule capable of inducing cleavage of approximately 1000 mRNA molecules. siRNA-mediated RNAi degradation of an mRNA is therefore more effective than currently available technologies for inhibiting expression of a target gene.

Elbashir SM et al. (2001), *supra*, has shown that synthetic siRNA of 21 and 22 nucleotides in length, and which have short 3' overhangs, are able to induce RNAi of target mRNA in a *Drosophila* cell lysate. Cultured mammalian cells also exhibit RNAi degradation with synthetic siRNA (Elbashir SM et al. (2001) *Nature*, 411: 494-498), and RNAi degradation induced by synthetic siRNA has recently been shown in living mice (McCaffrey AP et al. (2002), *Nature*, 418: 38-39; Xia H et al. (2002), *Nat. Biotech.* 20: 1006-1010). The therapeutic potential of siRNA-induced RNAi degradation has been demonstrated in several recent *in vitro* studies, including the siRNA-directed inhibition of HIV-1 infection (Novina CD et al. (2002), *Nat. Med.* 8: 681-686) and reduction of neurotoxic polyglutamine disease protein expression (Xia H et al. (2002), *supra*).

What is needed, therefore, are agents which selectively inhibit expression of VEGF or VEGF receptors in catalytic or sub-stoichiometric amounts.

#### **Summary of the Invention**

The present invention is directed to siRNAs which specifically target and cause RNAi-induced degradation of mRNA from VEGF, Flt-1 and Flk-1/KDR genes. The siRNA compounds and compositions of the invention are used to inhibit angiogenesis, in particular for the treatment of cancerous tumors, age-related macular degeneration, and other angiogenic diseases.

Thus, the invention provides an isolated siRNA which targets human VEGF mRNA, human Flt-1 mRNA, human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof. The siRNA comprises a sense RNA strand and an antisense RNA strand which form an RNA duplex. The sense RNA strand comprises a nucleotide sequence identical to a target sequence of about 19 to about 25 contiguous nucleotides in the target mRNA.



The invention also provides recombinant plasmids and viral vectors which express the siRNA of the invention, as well as pharmaceutical compositions comprising the siRNA of the invention and a pharmaceutically acceptable carrier.

The invention further provides a method of inhibiting expression of human VEGF mRNA, human Flt-1 mRNA, human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof, comprising administering to a subject an effective amount of the siRNA of the invention such that the target mRNA is degraded.

The invention further provides a method of inhibiting angiogenesis in a subject, comprising administering to a subject an effective amount of an siRNA targeted to human VEGF mRNA, human Flt-1 mRNA, human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof.

The invention further provides a method of treating an angiogenic disease, comprising administering to a subject in need of such treatment an effective amount of an siRNA targeted to human VEGF mRNA, human Flt-1 mRNA, human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof, such that angiogenesis associated with the angiogenic disease is inhibited.

#### **Brief Description of the Drawings**

**FIGS. 1A and 1B** are a histograms of VEGF concentration (in pg/ml) in hypoxic 293 and HeLa cells treated with no siRNA ("-"); nonspecific siRNA ("nonspecific"); or siRNA targeting human VEGF mRNA ("VEGF"). VEGF concentration (in pg/ml) in non-hypoxic 293 and HeLa cells is also shown. Each bar represents the average of four experiments, and the error is the standard deviation of the mean.

**FIG. 2** is a histogram of murine VEGF concentration (in pg/ml) in hypoxic NIH 3T3 cells treated with no siRNA ("-"); nonspecific siRNA ("nonspecific"); or siRNA targeting human VEGF mRNA ("VEGF"). Each bar represents the average of six experiments and the error is the standard deviation of the mean.

**FIG. 3** is a histogram of human VEGF concentration (pg/total protein) in retinas from mice injected with adenovirus expressing human VEGF ("AdVEGF") in the presence of either GFP siRNA (dark gray bar) or human VEGF siRNA (light

grey bar). Each bar represent the average of 5 eyes and the error bars represent the standard error of the mean.

FIG. 4 is a histogram showing the mean area (in  $\text{mm}^2$ ) of laser-induced CNV in control eyes given subretinal injections of GFP siRNA (N=9; "GFP siRNA"), and in eyes given subretinal injections of mouse VEGF siRNA (N=7; "Mouse VEGF siRNA"). The error bars represent the standard error of the mean.

FIG. 5 is a schematic representation of pAAVsiRNA, a cis-acting plasmid used to generate a recombinant AAV viral vector of the invention. "ITR": AAV inverted terminal repeats; "U6": U6 RNA promoters; "Sense": siRNA sense coding sequence; "Anti": siRNA antisense coding sequence; "PolyT": polythymidine termination signals.

Fig. 6 shows histograms of the mean area (in  $\text{mm}^2$ ) of laser-induced CNV in treatment in mouse eyes injected (A) subretinally or (B) intravitreally with a mouse anti-VEGF siRNA ("mVEGF1.siRNA") or control siRNA ("GFP1.siRNA"). The error bars represent the standard error of the mean. (C) is a histogram of the mean area (in  $\text{mm}^2$ ) of laser-induced CNV in mouse eyes injected intravitreally with: phosphate-buffered saline with no siRNA at 1 day post-laser induction ("PBS"; CNV area measured at 14 days post-laser induction); control siRNA at 14 days post-laser induction ("GFP1.siRNA"; CNV area measured at 21 days post-laser induction); or a mouse anti-VEGF siRNA at 14 days post-laser induction ("mVEGF1.siRNA"; CNV area measured at 21 days post-laser induction). The error bars represent the standard error of the mean.

Fig. 7 is a graph of the percent of VEGF ("%VEGF") protein in mouse eyes injected sub-retinally with human anti-VEGF siRNA ("Cand5") and control siRNA ("GFP1.siRNA") at 0 (n=2; pre-siRNA injection), 6 (n=3), 10 (n=3) and 14 (n=3) days post-injection.  $\%VEGF = ([VEGF] \text{ in the Cand5 eye} / [VEGF] \text{ in the GFP1.siRNA eye}) * 100$ .

### Detailed Description of the Invention

Unless otherwise indicated, all nucleic acid sequences herein are given in the 5' to 3' direction. Also, all deoxyribonucleotides in a nucleic acid sequence are

represented by capital letters (*e.g.*, deoxythymidine is “T”), and ribonucleotides in a nucleic acid sequence are represented by lower case letters (*e.g.*, uridine is “u”).

Compositions and methods comprising siRNA targeted to VEGF, Flt-1 or Flk-1/KDR mRNA are advantageously used to inhibit angiogenesis, in particular  
5 for the treatment of angiogenic disease. The siRNA of the invention are believed to cause the RNAi-mediated degradation of these mRNAs, so that the protein product of the VEGF, Flt-1 or Flk-1/KDR genes is not produced or is produced in reduced amounts. Because VEGF binding to the Flt-1 or Flk-1/KDR receptors is required for initiating and maintaining angiogenesis, the siRNA-mediated  
10 degradation of VEGF, Flt-1 or Flk-1/KDR mRNA inhibits the angiogenic process.

The invention therefore provides isolated siRNA comprising short double-stranded RNA from about 17 nucleotides to about 29 nucleotides in length, preferably from about 19 to about 25 nucleotides in length, that are targeted to the target mRNA. The siRNA comprise a sense RNA strand and a complementary  
15 antisense RNA strand annealed together by standard Watson-Crick base-pairing interactions (hereinafter “base-paired”). As is described in more detail below, the sense strand comprises a nucleic acid sequence which is identical to a target sequence contained within the target mRNA.

The sense and antisense strands of the present siRNA can comprise two  
20 complementary, single-stranded RNA molecules or can comprise a single molecule in which two complementary portions are base-paired and are covalently linked by a single-stranded “hairpin” area. Without wishing to be bound by any theory, it is believed that the hairpin area of the latter type of siRNA molecule is cleaved intracellularly by the “Dicer” protein (or its equivalent) to form an siRNA of two  
25 individual base-paired RNA molecules (see Tuschl, T. (2002), *supra*).

As used herein, “isolated” means altered or removed from the natural state through human intervention. For example, an siRNA naturally present in a living animal is not “isolated,” but a synthetic siRNA, or an siRNA partially or completely separated from the coexisting materials of its natural state is “isolated.”  
30 An isolated siRNA can exist in substantially purified form, or can exist in a non-native environment such as, for example, a cell into which the siRNA has been delivered.

As used herein, "target mRNA" means human VEGF, Flt-1 or Flk-1/KDR mRNA, mutant or alternative splice forms of human VEGF, Flt-1 or Flk-1/KDR mRNA, or mRNA from cognate VEGF, Flt-1 or Flk-1/KDR genes.

As used herein, a gene or mRNA which is "cognate" to human VEGF, Flt-1 or Flk-1/KDR is a gene or mRNA from another mammalian species which is homologous to human VEGF, Flt-1 or Flk-1/KDR. For example, the cognate VEGF mRNA from the mouse is given in SEQ ID NO: 1.

Splice variants of human VEGF are known, including VEGF<sub>121</sub> (SEQ ID NO: 2), VEGF<sub>165</sub> (SEQ ID NO: 3), VEGF<sub>189</sub> (SEQ ID NO: 4) and VEGF<sub>206</sub> (SEQ ID NO: 5). The mRNA transcribed from the human VEGF, Flt-1 (SEQ ID NO: 6) or Flk-1/KDR (SEQ ID NO: 7) genes can be analyzed for further alternative splice forms using techniques well-known in the art. Such techniques include reverse transcription-polymerase chain reaction (RT-PCR), northern blotting and *in-situ* hybridization. Techniques for analyzing mRNA sequences are described, for example, in Busting SA (2000), *J. Mol. Endocrinol.* 25: 169-193, the entire disclosure of which is herein incorporated by reference. Representative techniques for identifying alternatively spliced mRNAs are also described below.

For example, databases that contain nucleotide sequences related to a given disease gene can be used to identify alternatively spliced mRNA. Such databases include GenBank, Embase, and the Cancer Genome Anatomy Project (CGAP) database. The CGAP database, for example, contains expressed sequence tags (ESTs) from various types of human cancers. An mRNA or gene sequence from the VEGF, Flt-1 or Flk-1/KDR genes can be used to query such a database to determine whether ESTs representing alternatively spliced mRNAs have been found for these genes.

A technique called "RNase protection" can also be used to identify alternatively spliced VEGF, Flt-1 or Flk-1/KDR mRNAs. RNase protection involves translation of a gene sequence into synthetic RNA, which is hybridized to RNA derived from other cells; for example, cells from tissue at or near the site of neovascularization. The hybridized RNA is then incubated with enzymes that recognize RNA:RNA hybrid mismatches. Smaller than expected fragments indicate the presence of alternatively spliced mRNAs. The putative alternatively

spliced mRNAs can be cloned and sequenced by methods well known to those skilled in the art.

RT-PCR can also be used to identify alternatively spliced VEGF, Flt-1 or Flk-1/KDR mRNAs. In RT-PCR, mRNA from the diseased tissue is converted  
5 into cDNA by the enzyme reverse transcriptase, using methods well-known to those of ordinary skill in the art. The entire coding sequence of the cDNA is then amplified via PCR using a forward primer located in the 3' untranslated region, and a reverse primer located in the 5' untranslated region. The amplified products can be analyzed for alternative splice forms, for example by comparing the size of the  
10 amplified products with the size of the expected product from normally spliced mRNA, *e.g.*, by agarose gel electrophoresis. Any change in the size of the amplified product can indicate alternative splicing.

mRNA produced from mutant VEGF, Flt-1 or Flk-1/KDR genes can also be readily identified through the techniques described above for identifying alternative  
15 splice forms. As used herein, "mutant" VEGF, Flt-1 or Flk-1/KDR genes or mRNA include human VEGF, Flt-1 or Flk-1/KDR genes or mRNA which differ in sequence from the VEGF, Flt-1 or Flk-1/KDR sequences set forth herein. Thus, allelic forms of these genes, and the mRNA produced from them, are considered "mutants" for purposes of this invention.

20 It is understood that human VEGF, Flt-1 or Flk-1/KDR mRNA may contain target sequences in common with their respective alternative splice forms, cognates or mutants. A single siRNA comprising such a common targeting sequence can therefore induce RNAi-mediated degradation of different RNA types which contain the common targeting sequence.

25 The siRNA of the invention can comprise partially purified RNA, substantially pure RNA, synthetic RNA, or recombinantly produced RNA, as well as altered RNA that differs from naturally-occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the siRNA or  
30 to one or more internal nucleotides of the siRNA, including modifications that make the siRNA resistant to nuclease digestion.

One or both strands of the siRNA of the invention can also comprise a 3' overhang. As used herein, a "3' overhang" refers to at least one unpaired nucleotide extending from the 3'-end of a duplexed RNA strand.

Thus in one embodiment, the siRNA of the invention comprises at least one  
5 3' overhang of from 1 to about 6 nucleotides (which includes ribonucleotides or deoxynucleotides) in length, preferably from 1 to about 5 nucleotides in length, more preferably from 1 to about 4 nucleotides in length, and particularly preferably from about 2 to about 4 nucleotides in length.

In the embodiment in which both strands of the siRNA molecule comprise a  
10 3' overhang, the length of the overhangs can be the same or different for each strand. In a most preferred embodiment, the 3' overhang is present on both strands of the siRNA, and is 2 nucleotides in length. For example, each strand of the siRNA of the invention can comprise 3' overhangs of dithymidylic acid ("TT") or diuridylic acid ("uu").

15 In order to enhance the stability of the present siRNA, the 3' overhangs can be also stabilized against degradation. In one embodiment, the overhangs are stabilized by including purine nucleotides, such as adenosine or guanosine nucleotides. Alternatively, substitution of pyrimidine nucleotides by modified analogues, *e.g.*, substitution of uridine nucleotides in the 3' overhangs with 2'-  
20 deoxythymidine, is tolerated and does not affect the efficiency of RNAi degradation. In particular, the absence of a 2' hydroxyl in the 2'-deoxythymidine significantly enhances the nuclease resistance of the 3' overhang in tissue culture medium.

In certain embodiments, the siRNA of the invention comprises the sequence  
25 AA(N19)TT or NA(N21), where N is any nucleotide. These siRNA comprise approximately 30-70% GC, and preferably comprise approximately 50% G/C. The sequence of the sense siRNA strand corresponds to (N19)TT or N21 (*i.e.*, positions 3 to 23), respectively. In the latter case, the 3' end of the sense siRNA is converted to TT. The rationale for this sequence conversion is to generate a symmetric  
30 duplex with respect to the sequence composition of the sense and antisense strand 3' overhangs. The antisense RNA strand is then synthesized as the complement to positions 1 to 21 of the sense strand.

Because position 1 of the 23-nt sense strand in these embodiments is not recognized in a sequence-specific manner by the antisense strand, the 3'-most nucleotide residue of the antisense strand can be chosen deliberately. However, the penultimate nucleotide of the antisense strand (complementary to position 2 of the 23-nt sense strand in either embodiment) is generally complementary to the targeted sequence.

In another embodiment, the siRNA of the invention comprises the sequence NAR(N17)YNN, where R is a purine (*e.g.*, A or G) and Y is a pyrimidine (*e.g.*, C or U/T). The respective 21-nt sense and antisense RNA strands of this embodiment therefore generally begin with a purine nucleotide. Such siRNA can be expressed from pol III expression vectors without a change in targeting site, as expression of RNAs from pol III promoters is only believed to be efficient when the first transcribed nucleotide is a purine.

The siRNA of the invention can be targeted to any stretch of approximately 19-25 contiguous nucleotides in any of the target mRNA sequences (the "target sequence"). Techniques for selecting target sequences for siRNA are given, for example, in Tuschl T et al., "The siRNA User Guide," revised Oct. 11, 2002, the entire disclosure of which is herein incorporated by reference. "The siRNA User Guide" is available on the world wide web at a website maintained by Dr. Thomas Tuschl, Department of Cellular Biochemistry, AG 105, Max-Planck-Institute for Biophysical Chemistry, 37077 Göttingen, Germany, and can be found by accessing the website of the Max Planck Institute and searching with the keyword "siRNA." Thus, the sense strand of the present siRNA comprises a nucleotide sequence identical to any contiguous stretch of about 19 to about 25 nucleotides in the target mRNA.

Generally, a target sequence on the target mRNA can be selected from a given cDNA sequence corresponding to the target mRNA, preferably beginning 50 to 100 nt downstream (*i.e.*, in the 3' direction) from the start codon. The target sequence can, however, be located in the 5' or 3' untranslated regions, or in the region nearby the start codon (see, *e.g.*, the target sequences of SEQ ID NOS: 73 and 74 in Table 1 below, which are within 100 nt of the 5'-end of the VEGF<sub>121</sub> cDNA

For example, a suitable target sequence in the VEGF<sub>121</sub> cDNA sequence is:

TCATCACGAAGTGGTGAAG (SEQ ID NO: 8)

Thus, an siRNA of the invention targeting this sequence, and which has 3'  
5 uu overhangs on each strand (overhangs shown in bold), is:

5'-ucaucacgaaguggugaaguu-3' (SEQ ID NO: 9)

3'-uuaguagugcuuccaccacuuc-5' (SEQ ID NO: 10)

10 An siRNA of the invention targeting this same sequence, but having 3' TT  
overhangs on each strand (overhangs shown in bold) is:

5'-ucaucacgaaguggugaagTT-3' (SEQ ID NO: 11)

3'-TTaguagugcuuccaccacuuc-5' (SEQ ID NO: 12)

15

Other VEGF<sub>121</sub> target sequences from which siRNA of the invention can be  
derived are given in Table 1. It is understood that all VEGF<sub>121</sub> target sequences  
listed in Table 1 are within that portion of the VEGF<sub>121</sub> alternative splice form  
which is common to all human VEGF alternative splice forms. Thus, the VEGF<sub>121</sub>  
20 target sequences in Table 1 can also target VEGF<sub>165</sub>, VEGF<sub>189</sub> and VEGF<sub>206</sub>  
mRNA. Target sequences which target a specific VEGF isoform can also be  
readily identified. For example, a target sequence which targets VEGF<sub>165</sub> mRNA  
but not VEGF<sub>121</sub> mRNA is AACGTACTTGACAGATGTGACA (SEQ ID NO: 13).  
Exemplary target sequences for human Flt-1 are given in SEQ ID NOS: 91 – 504,  
25 and exemplary target sequences for human Flk-1/KDR are given in SEQ ID NOS:  
505 – 864.



Table 1 - VEGF Target Sequences

| target sequence      | SEQ ID NO: | target sequence      | SEQ ID NO: |
|----------------------|------------|----------------------|------------|
| GTTCATGGATGCTCTATCAG | 14         | TCCCTGTGGGCCTTGCTCA  | 30         |
| TCGAGACCCCTGGTGGACAT | 15         | GCATTTGTTGTACAAGAT   | 31         |
| TGACGAGGGCCTGGAGTGT  | 16         | GATCCGCAGACGTGTAAAT  | 32         |
| TGACGAGGGCCTGGAGTGT  | 17         | ATGTTCTCTGCAAAAACACA | 33         |
| CATCACCATGCAGATTATG  | 18         | TGTTCTCTGCAAAAACACAG | 34         |
| ACCTCACCAAGGCCAGCAC  | 19         | AAACACAGACTCGCGTTGC  | 35         |
| GGCCAGCACATAGGAGAGA  | 20         | AACACAGACTCGCGTTGCA  | 36         |
| CAAATGTGAATGCAGACCA  | 21         | ACACAGACTCGCGTTGCAA  | 37         |
| ATGTGAATGCAGACCAAAG  | 22         | CACAGACTCGCGTTGCAAG  | 38         |
| TGCAGACCAAAGAAAGATA  | 23         | GGCGAGGCAGCTTGAGTTA  | 39         |
| AGAAAGATAGAGCAAGACA  | 24         | ACGAACGTACTTGCAGATG  | 40         |
| GAAAGATAGAGCAAGACAA  | 25         | CGAACGTACTTGCAGATGT  | 41         |
| GATAGAGCAAGACAAGAAA  | 26         | CGTACTTGCAGATGTGACA  | 42         |
| GACAAAGAAAATCCCTGTGG | 27         | GTGTTCCAGGCTGCACCC   | 43         |
| GAAAATCCCTGTGGGCCTT  | 28         | GGAGGAGGGCAGAAATCATC | 44         |
| AATCCCTGTGGGCCTTGCT  | 29         | GTGGTGAAGTTTCATGGATG | 45         |

Table 1 (continued) - VEGF Target Sequences

| target sequence           | SEQ ID NO: | target sequence           | SEQ ID NO: |
|---------------------------|------------|---------------------------|------------|
| AATCATCACGAAAGTGGTGAAG    | 46         | AAGCATTGTGTTGTACAAGATCC   | 62         |
| AAGTTTCATGGATGTCCTATCAG   | 47         | AAGATCCGCAGACGTGTAAATGT   | 63         |
| AATCGAGAGACCCCTGGTGGACAT  | 48         | AAATGTTCTCTGCAAAAACACAGAG | 64         |
| AATGACGAGGGCCTGGAGTGT     | 49         | AAATGTTCTCTGCAAAAACACAGAC | 65         |
| AACATCACCATGCAGATTATG     | 50         | AAAAACACAGACTCGCGTTGCAA   | 66         |
| AAACCTCACCAAGGCCAGCAC     | 51         | AAACACACAGACTCGCGTTGCAAG  | 67         |
| AAGGCCAGCACATAGGAGAGA     | 52         | AAACACAGACTCGCGTTGCAAAGG  | 68         |
| AACAAATGTGAATGCAGACCA     | 53         | AACACAGACTCGCGTTGCAAAGGC  | 69         |
| AAATGTGAATGCAGACCAAAG     | 54         | AAGGCGAGGCAGCTTGAGTTAAA   | 70         |
| AATGCAGACCAAAGAAAAGATA    | 55         | AAACGAAACGTACTTGCAGATGTG  | 71         |
| AAAGAAAGATAGAGCAAAGACA    | 56         | AACGAACGTACTTGCAGATGTGA   | 72         |
| AAGAAAGATAGAGCAAAGACAA    | 57         | AAGTGGTCCCAGGCTGCACCCAT   | 73         |
| AAGATAGAGCAAAGACAAAGAAAAT | 58         | AAGGAGGAGGGCAGAGAATCATCAC | 74         |
| AAGACAAGAAAATCCCTGTGGGC   | 59         | AAGTGGTGAAGTTTCATGGATGTC  | 75         |
| AAGAAAAATCCCTGTGGGCCTTGC  | 60         | AAAATCCCTGTGGGCCTTGCCTCA  | 76         |
| AATCCCTGTGGGCCTTGTCTCAGA  | 61         | GGCAGAAATCATCACGAAGTGG    | 81         |

Table 1 (continued) - VEGF Target Sequences

| target sequence        | SEQ ID NO: | target sequence        | SEQ ID NO: |
|------------------------|------------|------------------------|------------|
| CCTGGTGGACATCTCCAGGA   | 82         | CACACACTCGCGTTGCAAGGC  | 87         |
| GAGATCGAGTACATCTTCAAG  | 83         | TCACCATGCAGATTATGCGGA  | 88         |
| TGGAGTGTGTGCCCACTGAGG  | 84         | TAGAGCAAGACAAAGAAAATCC | 89         |
| GAGCTTCCTACAGCACAAACAA | 85         | CCGCAGACGTGTAAATGTTC   | 90         |
| TTGCTCAGAGCGGAGAAAGCA  | 86         |                        |            |

The siRNA of the invention can be obtained using a number of techniques known to those of skill in the art. For example, the siRNA can be chemically synthesized or recombinantly produced using methods known in the art, such as the *Drosophila in vitro* system described in U.S. published application 2002/0086356 of Tuschl et al., the entire disclosure of which is  
5 herein incorporated by reference.

Preferably, the siRNA of the invention are chemically synthesized using appropriately protected ribonucleoside phosphoramidites and a conventional DNA/RNA synthesizer. The siRNA can be synthesized as two separate,  
10 complementary RNA molecules, or as a single RNA molecule with two complementary regions. Commercial suppliers of synthetic RNA molecules or synthesis reagents include Proligo (Hamburg, Germany), Dharmacon Research (Lafayette, CO, USA), Pierce Chemical (part of Perbio Science, Rockford, IL, USA), Glen Research (Sterling, VA, USA), ChemGenes (Ashland, MA, USA)  
15 and Cruachem (Glasgow, UK).

Alternatively, siRNA can also be expressed from recombinant circular or linear DNA plasmids using any suitable promoter. Suitable promoters for expressing siRNA of the invention from a plasmid include, for example, the U6 or H1 RNA pol III promoter sequences and the cytomegalovirus promoter.  
20 Selection of other suitable promoters is within the skill in the art. The recombinant plasmids of the invention can also comprise inducible or regulatable promoters for expression of the siRNA in a particular tissue or in a particular intracellular environment.

The siRNA expressed from recombinant plasmids can either be isolated  
25 from cultured cell expression systems by standard techniques, or can be expressed intracellularly at or near the area of neovascularization *in vivo*. The use of recombinant plasmids to deliver siRNA of the invention to cells *in vivo* is discussed in more detail below.

siRNA of the invention can be expressed from a recombinant plasmid  
30 either as two separate, complementary RNA molecules, or as a single RNA molecule with two complementary regions.

Selection of plasmids suitable for expressing siRNA of the invention, methods for inserting nucleic acid sequences for expressing the siRNA into the plasmid, and methods of delivering the recombinant plasmid to the cells of interest are within the skill in the art. See, for example Tuschl, T. (2002), *Nat. Biotechnol.*, 20: 446-448; Brummelkamp TR et al. (2002), *Science* 296: 550-553; Miyagishi M et al. (2002), *Nat. Biotechnol.* 20: 497-500; Paddison PJ et al. (2002), *Genes Dev.* 16: 948-958; Lee NS et al. (2002), *Nat. Biotechnol.* 20: 500-505; and Paul CP et al. (2002), *Nat. Biotechnol.* 20: 505-508, the entire disclosures of which are herein incorporated by reference.

10 A plasmid comprising nucleic acid sequences for expressing an siRNA of the invention is described in Example 7 below. That plasmid, called pAAVsiRNA, comprises a sense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter, and an antisense RNA strand coding sequence in operable  
15 connection with a polyT termination sequence under the control of a human U6 RNA promoter. The plasmid pAAVsiRNA is ultimately intended for use in producing an recombinant adeno-associated viral vector comprising the same nucleic acid sequences for expressing an siRNA of the invention.

As used herein, "in operable connection with a polyT termination  
20 sequence" means that the nucleic acid sequences encoding the sense or antisense strands are immediately adjacent to the polyT termination signal in the 5' direction. During transcription of the sense or antisense sequences from the plasmid, the polyT termination signals act to terminate transcription.

As used herein, "under the control" of a promoter means that the nucleic  
25 acid sequences encoding the sense or antisense strands are located 3' of the promoter, so that the promoter can initiate transcription of the sense or antisense coding sequences.

The siRNA of the invention can also be expressed from recombinant viral vectors intracellularly at or near the area of neovascularization *in vivo*. The  
30 recombinant viral vectors of the invention comprise sequences encoding the siRNA of the invention and any suitable promoter for expressing the siRNA sequences. Suitable promoters include, for example, the U6 or H1 RNA pol III

promoter sequences and the cytomegalovirus promoter. Selection of other suitable promoters is within the skill in the art. The recombinant viral vectors of the invention can also comprise inducible or regulatable promoters for expression of the siRNA in a particular tissue or in a particular intracellular environment. The use of recombinant viral vectors to deliver siRNA of the invention to cells *in vivo* is discussed in more detail below.

siRNA of the invention can be expressed from a recombinant viral vector either as two separate, complementary RNA molecules, or as a single RNA molecule with two complementary regions.

Any viral vector capable of accepting the coding sequences for the siRNA molecule(s) to be expressed can be used, for example vectors derived from adenovirus (AV); adeno-associated virus (AAV); retroviruses (e.g. lentiviruses (LV), Rhabdoviruses, murine leukemia virus); herpes virus, and the like. The tropism of the viral vectors can also be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses. For example, an AAV vector of the invention can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like.

Selection of recombinant viral vectors suitable for use in the invention, methods for inserting nucleic acid sequences for expressing the siRNA into the vector, and methods of delivering the viral vector to the cells of interest are within the skill in the art. See, for example, Dornburg R (1995), *Gene Therap.* 2: 301-310; Eglitis MA (1988), *Biotechniques* 6: 608-614; Miller AD (1990), *Hum Gene Therap.* 1: 5-14; and Anderson WF (1998), *Nature* 392: 25-30, the entire disclosures of which are herein incorporated by reference.

Preferred viral vectors are those derived from AV and AAV. In a particularly preferred embodiment, the siRNA of the invention is expressed as two separate, complementary single-stranded RNA molecules from a recombinant AAV vector comprising, for example, either the U6 or H1 RNA promoters, or the cytomegalovirus (CMV) promoter.

A suitable AV vector for expressing the siRNA of the invention, a method for constructing the recombinant AV vector, and a method for

delivering the vector into target cells, are described in Xia H et al. (2002), *Nat. Biotech.* 20: 1006-1010.

Suitable AAV vectors for expressing the siRNA of the invention, methods for constructing the recombinant AAV vector, and methods for  
5 delivering the vectors into target cells are described in Samulski R et al. (1987), *J. Virol.* 61: 3096-3101; Fisher KJ et al. (1996), *J. Virol.*, 70: 520-532; Samulski R et al. (1989), *J. Virol.* 63: 3822-3826; U.S. Pat. No. 5,252,479; U.S. Pat. No. 5,139,941; International Patent Application No. WO 94/13788; and International Patent Application No. WO 93/24641, the entire disclosures of  
10 which are herein incorporated by reference. An exemplary method for generating a recombinant AAV vector of the invention is described in Example 7 below.

The ability of an siRNA containing a given target sequence to cause RNAi-mediated degradation of the target mRNA can be evaluated using  
15 standard techniques for measuring the levels of RNA or protein in cells. For example, siRNA of the invention can be delivered to cultured cells, and the levels of target mRNA can be measured by Northern blot or dot blotting techniques, or by quantitative RT-PCR. Alternatively, the levels of VEGF, Flt-1 or Flk-1/KDR receptor protein in the cultured cells can be measured by ELISA  
20 or Western blot. A suitable cell culture system for measuring the effect of the present siRNA on target mRNA or protein levels is described in Example 1 below.

RNAi-mediated degradation of target mRNA by an siRNA containing a given target sequence can also be evaluated with animal models of  
25 neovascularization, such as the ROP or CNV mouse models. For example, areas of neovascularization in an ROP or CNV mouse can be measured before and after administration of an siRNA. A reduction in the areas of neovascularization in these models upon administration of the siRNA indicates the down-regulation of the target mRNA (see Example 6 below).

30 As discussed above, the siRNA of the invention target and cause the RNAi-mediated degradation of VEGF, Flt-1 or Flk-1/KDR mRNA, or alternative splice forms, mutants or cognates thereof. Degradation of the target

mRNA by the present siRNA reduces the production of a functional gene product from the VEGF, Flt-1 or Flk-1/KDR genes. Thus, the invention provides a method of inhibiting expression of VEGF, Flt-1 or Flk-1/KDR in a subject, comprising administering an effective amount of an siRNA of the invention to the subject, such that the target mRNA is degraded. As the products of the VEGF, Flt-1 and Flk-1/KDR genes are required for initiating and maintaining angiogenesis, the invention also provides a method of inhibiting angiogenesis in a subject by the RNAi-mediated degradation of the target mRNA by the present siRNA.

10 As used herein, a "subject" includes a human being or non-human animal. Preferably, the subject is a human being.

As used herein, an "effective amount" of the siRNA is an amount sufficient to cause RNAi-mediated degradation of the target mRNA, or an amount sufficient to inhibit the progression of angiogenesis in a subject.

15 RNAi-mediated degradation of the target mRNA can be detected by measuring levels of the target mRNA or protein in the cells of a subject, using standard techniques for isolating and quantifying mRNA or protein as described above.

Inhibition of angiogenesis can be evaluated by directly measuring the progress of pathogenic or nonpathogenic angiogenesis in a subject; for example, by observing the size of a neovascularized area before and after treatment with the siRNA of the invention. An inhibition of angiogenesis is indicated if the size of the neovascularized area stays the same or is reduced. Techniques for observing and measuring the size of neovascularized areas in a subject are within the skill in the art; for example, areas of choroid neovascularization can be observed by ophthalmoscopy.

20 Inhibition of angiogenesis can also be inferred through observing a change or reversal in a pathogenic condition associated with the angiogenesis. For example, in ARMD, a slowing, halting or reversal of vision loss indicates an inhibition of angiogenesis in the choroid. For tumors, a slowing, halting or reversal of tumor growth, or a slowing or halting of tumor metastasis, indicates an inhibition of angiogenesis at or near the tumor site. Inhibition of non-



pathogenic angiogenesis can also be inferred from, for example, fat loss or a reduction in cholesterol levels upon administration of the siRNA of the invention.

It is understood that the siRNA of the invention can degrade the target mRNA (and thus inhibit angiogenesis) in substoichiometric amounts. Without wishing to be bound by any theory, it is believed that the siRNA of the invention causes degradation of the target mRNA in a catalytic manner. Thus, compared to standard anti-angiogenic therapies, significantly less siRNA needs to be delivered at or near the site of neovascularization to have a therapeutic effect.

One skilled in the art can readily determine an effective amount of the siRNA of the invention to be administered to a given subject, by taking into account factors such as the size and weight of the subject; the extent of the neovascularization or disease penetration; the age, health and sex of the subject; the route of administration; and whether the administration is regional or systemic. Generally, an effective amount of the siRNA of the invention comprises an intercellular concentration at or near the neovascularization site of from about 1 nanomolar (nM) to about 100 nM, preferably from about 2 nM to about 50 nM, more preferably from about 2.5 nM to about 10 nM. It is contemplated that greater or lesser amounts of siRNA can be administered.

The present methods can be used to inhibit angiogenesis which is non-pathogenic; *i.e.*, angiogenesis which results from normal processes in the subject. Examples of non-pathogenic angiogenesis include endometrial neovascularization, and processes involved in the production of fatty tissues or cholesterol. Thus, the invention provides a method for inhibiting non-pathogenic angiogenesis, *e.g.*, for controlling weight or promoting fat loss, for reducing cholesterol levels, or as an abortifacient.

The present methods can also inhibit angiogenesis which is associated with an angiogenic disease; *i.e.*, a disease in which pathogenicity is associated with inappropriate or uncontrolled angiogenesis. For example, most cancerous solid tumors generate an adequate blood supply for themselves by inducing angiogenesis in and around the tumor site. This tumor-induced angiogenesis is

often required for tumor growth, and also allows metastatic cells to enter the bloodstream.

Other angiogenic diseases include diabetic retinopathy, age-related macular degeneration (ARMD), psoriasis, rheumatoid arthritis and other inflammatory diseases. These diseases are characterized by the destruction of normal tissue by newly formed blood vessels in the area of neovascularization. For example, in ARMD, the choroid is invaded and destroyed by capillaries. The angiogenesis-driven destruction of the choroid in ARMD eventually leads to partial or full blindness.

Preferably, an siRNA of the invention is used to inhibit the growth or metastasis of solid tumors associated with cancers; for example breast cancer, lung cancer, head and neck cancer, brain cancer, abdominal cancer, colon cancer, colorectal cancer, esophagus cancer, gastrointestinal cancer, glioma, liver cancer, tongue cancer, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, Wilm's tumor, multiple myeloma; skin cancer (*e.g.*, melanoma), lymphomas and blood cancer.

More preferably, an siRNA of the invention is used to inhibit choroidal neovascularization in age-related macular degeneration.

For treating angiogenic diseases, the siRNA of the invention can be administered to a subject in combination with a pharmaceutical agent which is different from the present siRNA. Alternatively, the siRNA of the invention can be administered to a subject in combination with another therapeutic method designed to treat the angiogenic disease. For example, the siRNA of the invention can be administered in combination with therapeutic methods currently employed for treating cancer or preventing tumor metastasis (*e.g.*, radiation therapy, chemotherapy, and surgery). For treating tumors, the siRNA of the invention is preferably administered to a subject in combination with radiation therapy, or in combination with chemotherapeutic agents such as cisplatin, carboplatin, cyclophosphamide, 5-fluorouracil, adriamycin, daunorubicin or tamoxifen.

In the present methods, the present siRNA can be administered to the subject either as naked siRNA, in conjunction with a delivery reagent, or as a recombinant plasmid or viral vector which expresses the siRNA.

Suitable delivery reagents for administration in conjunction with the present siRNA include the Mirus Transit TKO lipophilic reagent; lipofectin; lipofectamine; cellfectin; or polycations (e.g., polylysine), or liposomes. A preferred delivery reagent is a liposome.

Liposomes can aid in the delivery of the siRNA to a particular tissue, such as retinal or tumor tissue, and can also increase the blood half-life of the siRNA. Liposomes suitable for use in the invention are formed from standard vesicle-forming lipids, which generally include neutral or negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of factors such as the desired liposome size and half-life of the liposomes in the blood stream. A variety of methods are known for preparing liposomes, for example as described in Szoka et al. (1980), *Ann. Rev. Biophys. Bioeng.* 9: 467; and U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, the entire disclosures of which are herein incorporated by reference.

Preferably, the liposomes encapsulating the present siRNA comprises a ligand molecule that can target the liposome to a particular cell or tissue at or near the site of angiogenesis. Ligands which bind to receptors prevalent in tumor or vascular endothelial cells, such as monoclonal antibodies that bind to tumor antigens or endothelial cell surface antigens, are preferred.

Particularly preferably, the liposomes encapsulating the present siRNA are modified so as to avoid clearance by the mononuclear macrophage and reticuloendothelial systems, for example by having opsonization-inhibition moieties bound to the surface of the structure. In one embodiment, a liposome of the invention can comprise both opsonization-inhibition moieties and a ligand.

Opsonization-inhibiting moieties for use in preparing the liposomes of the invention are typically large hydrophilic polymers that are bound to the liposome membrane. As used herein, an opsonization inhibiting moiety is

“bound” to a liposome membrane when it is chemically or physically attached to the membrane, *e.g.*, by the intercalation of a lipid-soluble anchor into the membrane itself, or by binding directly to active groups of membrane lipids. These opsonization-inhibiting hydrophilic polymers form a protective surface layer which significantly decreases the uptake of the liposomes by the macrophage-monocyte system (“MMS”) and reticuloendothelial system (“RES”); *e.g.*, as described in U.S. Pat. No. 4,920,016, the entire disclosure of which is herein incorporated by reference. Liposomes modified with opsonization-inhibition moieties thus remain in the circulation much longer than unmodified liposomes. For this reason, such liposomes are sometimes called “stealth” liposomes.

Stealth liposomes are known to accumulate in tissues fed by porous or “leaky” microvasculature. Thus, target tissue characterized by such microvasculature defects, for example solid tumors, will efficiently accumulate these liposomes; *see* Gabizon, et al. (1988), *P.N.A.S., USA*, 18: 6949-53. In addition, the reduced uptake by the RES lowers the toxicity of stealth liposomes by preventing significant accumulation in the liver and spleen. Thus, liposomes of the invention that are modified with opsonization-inhibition moieties can deliver the present siRNA to tumor cells.

Opsonization inhibiting moieties suitable for modifying liposomes are preferably water-soluble polymers with a number-average molecular weight from about 500 to about 40,000 daltons, and more preferably from about 2,000 to about 20,000 daltons. Such polymers include polyethylene glycol (PEG) or polypropylene glycol (PPG) derivatives; *e.g.*, methoxy PEG or PPG, and PEG or PPG stearate; synthetic polymers such as polyacrylamide or poly N-vinyl pyrrolidone; linear, branched, or dendrimeric polyamidoamines; polyacrylic acids; polyalcohols, *e.g.*, polyvinylalcohol and polyxylitol to which carboxylic or amino groups are chemically linked, as well as gangliosides, such as ganglioside GM<sub>1</sub>. Copolymers of PEG, methoxy PEG, or methoxy PPG, or derivatives thereof, are also suitable. In addition, the opsonization inhibiting polymer can be a block copolymer of PEG and either a polyamino acid, polysaccharide, polyamidoamine, polyethyleneamine, or polynucleotide. The

opsonization inhibiting polymers can also be natural polysaccharides containing amino acids or carboxylic acids, e.g., galacturonic acid, glucuronic acid, mannuronic acid, hyaluronic acid, pectic acid, neuraminic acid, alginic acid, carrageenan; aminated polysaccharides or oligosaccharides (linear or branched);  
5 or carboxylated polysaccharides or oligosaccharides, e.g., reacted with derivatives of carbonic acids with resultant linking of carboxylic groups.

Preferably, the opsonization-inhibiting moiety is a PEG, PPG, or derivatives thereof. Liposomes modified with PEG or PEG-derivatives are sometimes called "PEGylated liposomes."

10 The opsonization inhibiting moiety can be bound to the liposome membrane by any one of numerous well-known techniques. For example, an N-hydroxysuccinimide ester of PEG can be bound to a phosphatidyl-ethanolamine lipid-soluble anchor, and then bound to a membrane. Similarly, a dextran polymer can be derivatized with a stearylamine lipid-soluble anchor via  
15 reductive amination using  $\text{Na}(\text{CN})\text{BH}_3$  and a solvent mixture such as tetrahydrofuran and water in a 30:12 ratio at 60 °C.

Recombinant plasmids which express siRNA of the invention are discussed above. Such recombinant plasmids can also be administered directly or in conjunction with a suitable delivery reagent, including the Mirus Transit  
20 LT1 lipophilic reagent; lipofectin; lipofectamine; cellfectin; polycations (e.g., polylysine) or liposomes. Recombinant viral vectors which express siRNA of the invention are also discussed above, and methods for delivering such vectors to an area of neovascularization in a patient are within the skill in the art.

The siRNA of the invention can be administered to the subject by any  
25 means suitable for delivering the siRNA to the cells of the tissue at or near the area of neovascularization. For example, the siRNA can be administered by gene gun, electroporation, or by other suitable parenteral or enteral administration routes.

Suitable enteral administration routes include oral, rectal, or intranasal  
30 delivery.

Suitable parenteral administration routes include intravascular administration (e.g. intravenous bolus injection, intravenous infusion, intra-

arterial bolus injection, intra-arterial infusion and catheter instillation into the vasculature); peri- and intra-tissue administration (*e.g.*, peri-tumoral and intra-tumoral injection, intra-retinal injection or subretinal injection); subcutaneous injection or deposition including subcutaneous infusion (such as by osmotic pumps); direct (*e.g.*, topical) application to the area at or near the site of neovascularization, for example by a catheter or other placement device (*e.g.*, a corneal pellet or a suppository, eye-dropper, or an implant comprising a porous, non-porous, or gelatinous material); and inhalation. Suitable placement devices include the ocular implants described in U.S. Pat. Nos. 5,902,598 and 6,375,972, and the biodegradable ocular implants described in U.S. Pat. No 6,331,313, the entire disclosures of which are herein incorporated by reference. Such ocular implants are available from Control Delivery Systems, Inc. (Watertown, MA) and Oculex Pharmaceuticals, Inc. (Sunnyvale, CA).

In a preferred embodiment, injections or infusions of the siRNA are given at or near the site of neovascularization. More preferably, the siRNA is administered topically to the eye, *e.g.* in liquid or gel form to the lower eye lid or conjunctival cul-de-sac, as is within the skill in the art (see, *e.g.*, Acheampong AA et al, 2002, *Drug Metabol. and Disposition* 30: 421-429, the entire disclosure of which is herein incorporated by reference).

Typically, the siRNA of the invention is administered topically to the eye in amounts of from about 5 microliters to about 75 microliters, for example from about 7 microliters to about 50 microliters, preferably from about 10 microliters to about 30 microliters. It is understood that topical instillation in the eye of siRNA in volumes greater than 75 microliters can result in loss of siRNA from the eye through spillage and drainage. Thus, it is preferable to administer a high concentration of siRNA (*e.g.*, 100-1000 nM) in as small a volume as possible.

A particularly preferred parenteral administration route is intraocular administration. It is understood that intraocular administration of the present siRNA can be accomplished by injection or direct (*e.g.*, topical) administration to the eye, as long as the administration route allows the siRNA to enter the eye. In addition to the topical routes of administration to the eye described above,

suitable intraocular routes of administration include intravitreal, intraretinal, subretinal, subtenon, peri- and retro-orbital, trans-corneal and trans-scleral administration. Such intraocular administration routes are within the skill in the art; see, *e.g.*, and Acheampong AA et al, 2002, *supra*; and Bennett et al. (1996),  
5 *Hum. Gene Ther.* 7: 1763-1769 and Ambati J et al., 2002, *Progress in Retinal and Eye Res.* 21: 145-151, the entire disclosures of which are herein incorporated by reference.

The siRNA of the invention can be administered in a single dose or in multiple doses. Where the administration of the siRNA of the invention is by  
10 infusion, the infusion can be a single sustained dose or can be delivered by multiple infusions. Injection of the agent directly into the tissue is at or near the site of neovascularization preferred. Multiple injections of the agent into the tissue at or near the site of neovascularization are particularly preferred.

One skilled in the art can also readily determine an appropriate dosage  
15 regimen for administering the siRNA of the invention to a given subject. For example, the siRNA can be administered to the subject once, such as by a single injection or deposition at or near the neovascularization site. Alternatively, the siRNA can be administered to a subject multiple times daily or weekly. For example, the siRNA can be administered to a subject once weekly for a period of  
20 from about three to about twenty-eight weeks, more preferably from about seven to about ten weeks. In a preferred dosage regimen, the siRNA is injected at or near the site of neovascularization (*e.g.*, intravitreally) once a week for seven weeks. It is understood that periodic administrations of the siRNA of the invention for an indefinite length of time may be necessary for subjects suffering from a chronic  
25 neovascularization disease, such as wet ARMD or diabetic retinopathy.

Where a dosage regimen comprises multiple administrations, it is understood that the effective amount of siRNA administered to the subject can comprise the total amount of siRNA administered over the entire dosage regimen.

The siRNA of the invention are preferably formulated as  
30 pharmaceutical compositions prior to administering to a subject, according to techniques known in the art. Pharmaceutical compositions of the present invention are characterized as being at least sterile and pyrogen-free. As used

herein, "pharmaceutical formulations" include formulations for human and veterinary use. Methods for preparing pharmaceutical compositions of the invention are within the skill in the art, for example as described in *Remington's Pharmaceutical Science*, 17th ed., Mack Publishing Company, Easton, Pa. 5 (1985), the entire disclosure of which is herein incorporated by reference.

The present pharmaceutical formulations comprise an siRNA of the invention (e.g., 0.1 to 90% by weight), or a physiologically acceptable salt thereof, mixed with a physiologically acceptable carrier medium. Preferred physiologically acceptable carrier media are water, buffered water, saline 10 solutions (e.g., normal saline or balanced saline solutions such as Hank's or Earle's balanced salt solutions), 0.4% saline, 0.3% glycine, hyaluronic acid and the like.

Pharmaceutical compositions of the invention can also comprise conventional pharmaceutical excipients and/or additives. Suitable 15 pharmaceutical excipients include stabilizers, antioxidants, osmolality adjusting agents, buffers, and pH adjusting agents. Suitable additives include physiologically biocompatible buffers (e.g., tromethamine hydrochloride), additions of chelants (such as, for example, DTPA or DTPA-bisamide) or calcium chelate complexes (as for example calcium DTPA, CaNaDTPA- 20 bisamide), or, optionally, additions of calcium or sodium salts (for example, calcium chloride, calcium ascorbate, calcium gluconate or calcium lactate). Pharmaceutical compositions of the invention can be packaged for use in liquid form, or can be lyophilized.

For topical administration to the eye, conventional intraocular delivery 25 reagents can be used. For example, pharmaceutical compositions of the invention for topical intraocular delivery can comprise saline solutions as described above, corneal penetration enhancers, insoluble particles, petrolatum or other gel-based ointments, polymers which undergo a viscosity increase upon instillation in the eye, or mucoadhesive polymers. Preferably, the intraocular 30 delivery reagent increases corneal penetration, or prolongs precorneal retention of the siRNA through viscosity effects or by establishing physicochemical interactions with the mucin layer covering the corneal epithelium.



Suitable insoluble particles for topical intraocular delivery include the calcium phosphate particles described in U.S. Pat. No. 6,355,271 of Bell et al., the entire disclosure of which is herein incorporated by reference. Suitable polymers which undergo a viscosity increase upon instillation in the eye include  
5 polyethylenepolyoxypropylene block copolymers such as poloxamer 407 (*e.g.*, at a concentration of 25%), cellulose acetophthalate (*e.g.*, at a concentration of 30%), or a low-acetyl gellan gum such as Gelrite® (available from CP Kelco, Wilmington, DE). Suitable mucoadhesive polymers include hydrocolloids with multiple hydrophilic functional groups such as carboxyl, hydroxyl, amide and/or  
10 sulfate groups; for example, hydroxypropylcellulose, polyacrylic acid, high-molecular weight polyethylene glycols (*e.g.*, >200,000 number average molecular weight), dextrans, hyaluronic acid, polygalacturonic acid, and xylocan. Suitable corneal penetration enhancers include cyclodextrins, benzalkonium chloride, polyoxyethylene glycol lauryl ether (*e.g.*, Brij® 35),  
15 polyoxyethylene glycol stearyl ether (*e.g.*, Brij® 78), polyoxyethylene glycol oleyl ether (*e.g.*, Brij® 98), ethylene diamine tetraacetic acid (EDTA), digitonin, sodium taurocholate, saponins and polyoxyethylated castor oil such as Cremaphor EL.

For solid compositions, conventional nontoxic solid carriers can be used;  
20 for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.

For example, a solid pharmaceutical composition for oral administration can comprise any of the carriers and excipients listed above and 10-95%,  
25 preferably 25%-75%, of one or more siRNA of the invention. A pharmaceutical composition for aerosol (inhalational) administration can comprise 0.01-20% by weight, preferably 1%-10% by weight, of one or more siRNA of the invention encapsulated in a liposome as described above, and propellant. A carrier can also be included as desired; *e.g.*, lecithin for intranasal delivery.

30

The invention will now be illustrated with the following non-limiting examples. The animal experiments described in Examples 4-6 and 8-9 were

performed using the University of Pennsylvania institutional guidelines for the care and use of animals in research. The animal experiment described in Example 10 will be performed in accordance with the Standard Operating Procedures of Sierra Biomedical, 587 Dunn Circle, Sparks, NV, 89431.

5

**Example 1 - siRNA Transfection and Hypoxia Induction *In Vitro***

*siRNA Design* - A 19 nt sequence located 329 nt from the 5' end of human VEGF mRNA was chosen as a target sequence:  
10 AAACCTCACCAAGGCCAGCAC (SEQ ID NO: 51). To ensure that it was not contained in the mRNA from any other genes, this target sequence was entered into the BLAST search engine provided by NCBI. The use of the BLAST algorithm is described in Altschul et al. (1990), *J. Mol. Biol.* 215: 403-410 and Altschul et al. (1997), *Nucleic Acids Res.* 25: 3389-3402, the  
15 disclosures of which are herein incorporated by reference in their entirety. As no other mRNA was found which contained the target sequence, an siRNA duplex was synthesized to target this sequence (Dharmacon Research, Inc., Lafayette, CO).

The siRNA duplex had the following sense and antisense strands.

20

sense:

5'-accucaccaaggccagcacTT-3' (SEQ ID NO: 77).

antisense:

5'-gugcuggccuuggugagguTT-3' (SEQ ID NO: 78).

25

Together, the siRNA sense and antisense strands formed a 19 nt double-stranded siRNA with TT 3' overhangs (shown in bold) on each strand. This siRNA was termed "Candidate 5" or "Cand5." Other siRNA which target human VEGF mRNA were designed and tested as described for Cand5.

An siRNA targeting the following sequence in green fluorescent protein  
30 (GFP) mRNA was used as a nonspecific control: GGCTACGTCCAGCGCACC (SEQ ID NO: 79). The siRNA was purchased from Dharmacon (Lafayette, CO).

*siRNA Transfection and Hypoxia Induction* In Vitro - Human cell lines (293; Hela and ARPE19) were separately seeded into 24-well plates in 250 microliters of complete DMEM medium one day prior to transfection, so that the cells were ~50% confluent at the time of transfection. Cells were transfected with 2.5 nM Cand5 siRNA, and with either no siRNA or 2.5 nM non-specific siRNA (targeting GFP) as controls. Transfections were performed in all cell lines with the "Transit TKO Transfection" reagent, as recommended by the manufacturer (Mirus).

Twenty four hours after transfection, hypoxia was induced in the cells by the addition of desferoxamide mesylate to a final concentration of 130 micromolar in each well. Twenty four hours post-transfection, the cell culture medium was removed from all wells, and a human VEGF ELISA (R&D systems, Minneapolis, MN) was performed on the culture medium as described in the Quantikine human VEGF ELISA protocol available from the manufacturer, the entire disclosure of which is herein incorporated by reference.

As can be seen in Fig. 1, RNAi degradation induced by Cand5 siRNA significantly reduces the concentration of VEGF produced by the hypoxic 293 and HeLa cells. There was essentially no difference in the amount of VEGF produced by hypoxic cells treated with either no siRNA or the non-specific siRNA control. Similar results were also seen with human ARPE19 cells treated under the same conditions. Thus, RNA interference with VEGF-targeted siRNA disrupts the pathogenic up-regulation of VEGF in human cultured cells *in vitro*.

The experiment outlined above was repeated on mouse NIH 3T3 cells using a mouse-specific VEGF siRNA (see Example 6 below), and VEGF production was quantified with a mouse VEGF ELISA (R&D systems, Minneapolis, MN) as described in the Quantikine mouse VEGF ELISA protocol available from the manufacturer, the entire disclosure of which is herein incorporated by reference. Results similar to those reported in Fig. 1 for the human cell lines were obtained.

**Example 2 - Effect of Increasing siRNA Concentration on VEGF Production in Human Cultured Cells**

The experiment outlined in Example 1 was repeated with human 293, HeLa and ARPE19 cells using a range of siRNA concentrations from 10 nM to 50 nM. The ability of the Cand5 siRNA to down-regulate VEGF production increased moderately up to approximately 13 nM siRNA, but a plateau effect was seen above this concentration. These results highlight the catalytic nature of siRNA-mediated RNAi degradation of mRNA, as the plateau effect appears to reflect VEGF production from the few cells not transfected with the siRNA. For the majority of cells which had been transfected with the siRNA, the increased VEGF mRNA production induced by the hypoxia is outstripped by the siRNA-induced degradation of the target mRNA at siRNA concentrations greater than about 13 nM.

15

**Example 3 - Specificity of siRNA Targeting**

NIH 3T3 mouse fibroblasts were grown in 24-well plates under standard conditions, so that the cells were ~50% confluent one day prior to transfection. The human VEGF siRNA Cand5 was transfected into a NIH 3T3 mouse fibroblasts as in Example 1. Hypoxia was then induced in the transfected cells, and murine VEGF concentrations were measured by ELISA as in Example 1.

The sequence targeted by the human VEGF siRNA Cand5 differs from the murine VEGF mRNA by one nucleotide. As can be seen in Fig. 2, the human VEGF siRNA has no affect on the ability of the mouse cells to up-regulate mouse VEGF after hypoxia. These results show that siRNA induced RNAi degradation is sequence-specific to within a one nucleotide resolution.

25

**Example 4 - *In Vivo* delivery of siRNA to Murine Retinal Pigment Epithelial Cells**

30

VEGF is upregulated in the retinal pigment epithelial (RPE) cells of human patients with age-related macular degeneration (ARMD). To show that functional siRNA can be delivered to RPE cells *in vivo*, GFP was expressed in

mouse retinas with a recombinant adenovirus, and GFP expression was silenced with siRNA. The experiment was conducted as follows.

One eye from each of five adult C57/Black6 mice (Jackson Labs, Bar Harbor, ME) was injected subretinally as described in Bennett et al. (1996),  
5 *supra.*, with a mixture containing  $\sim 1 \times 10^8$  particles of adenovirus containing eGFP driven by the CMV promoter and 20 picomoles of siRNA targeting eGFP conjugated with transit TKO reagent (Mirus).

As positive control, the contralateral eyes were injected with a mixture containing  $\sim 1 \times 10^8$  particles of adenovirus containing eGFP driven by the CMV  
10 promoter and 20 picomoles of siRNA targeting human VEGF conjugated with transit TKO reagent (Mirus). Expression of GFP was detected by fundus ophthalmoscopy 48 hours and 60 hours after injection. Animals were sacrificed at either 48 hours or 60 hours post-injection. The eyes were enucleated and fixed in 4% paraformaldehyde, and were prepared either as flat mounts or were  
15 processed into 10 micron cryosections for fluorescent microscopy.

No GFP fluorescence was detectable by ophthalmoscopy in the eyes which received the siRNA targeted to GFP mRNA in 4 out of 5 mice, whereas GFP fluorescence was detectable in the contralateral eye which received the non-specific control siRNA. A representative flat mount analyzed by  
20 fluorescence microscopy showed a lack of GFP fluorescence in the eye which received GFP siRNA, as compared to an eye that received the non-specific control siRNA. Cryosections of another retina showed that the recombinant adenovirus efficiently targets the RPE cells, and when the adenovirus is accompanied by siRNA targeted to GFP mRNA, expression of the GFP  
25 transgene is halted.

While there is some GFP fluorescence detectable by fluorescence microscopy in eyes that received siRNA targeted to GFP mRNA, the fluorescence is greatly suppressed as compared to controls that received non-specific siRNA. These data demonstrate that functional siRNA can be delivered  
30 *in vivo* to RPE cells.

**Example 5 - *In Vivo* Expression and siRNA-Induced RNAi Degradation of Human VEGF in Murine Retinas**

In order to demonstrate that siRNA targeted to VEGF functioned *in vivo*,  
5 an exogenous human VEGF expression cassette was delivered to mouse RPE  
cells via an adenovirus by subretinal injection, as in Example 4. One eye  
received Cand5 siRNA, and the contralateral eye received siRNA targeted to  
GFP mRNA. The animals were sacrificed 60 hours post-injection, and the  
injected eyes were removed and snap frozen in liquid N<sub>2</sub> following enucleation.  
10 The eyes were then homogenized in lysis buffer, and total protein was measured  
using a standard Bradford protein assay (Roche, Germany). The samples were  
normalized for total protein prior to assaying for human VEGF by ELISA as  
described in Example 1.

The expression of VEGF was somewhat variable from animal to animal.  
15 The variability of VEGF levels correlated well to those observed in the GFP  
experiments of Example 4, and can be attributed to some error from injection to  
injection, and the differential ability of adenovirus to deliver the target gene in  
each animal. However, there was a significant attenuation of VEGF expression  
in each eye that received VEGF siRNA, as compared to the eyes receiving the  
20 non-specific control siRNA (Figure 4). These data indicate that the Cand5  
siRNA was potent and effective in silencing human VEGF expression in murine  
RPE cells *in vivo*.

**Example 6 - Inhibition of Choroidal Neovascularization in the  
25 Mouse CNV Model**

There is evidence that choroidal neovascularization in ARMD is due to  
the upregulation of VEGF in the RPE cells. This human pathologic condition  
can be modeled in the mouse by using a laser to burn a spot on the retina ("laser  
30 photo-coagulation" or "laser induction"). During the healing process, VEGF is  
believed to be up-regulated in the RPE cells of the burned region, leading to re-  
vascularization of the choroid. This model is called the mouse choroidal  
neovascularization ("CNV") model.

For rescue of the mouse CNV model, a mouse siRNA was designed that  
35 incorporated a one nucleotide change from the human "Cand5" siRNA from

Example 1. The mouse siRNA specifically targeted mouse VEGF mRNA at the sequence AAACCUCACCAAAGCCAGCAC (SEQ ID NO: 80). Other siRNA that target mouse VEGF were also designed and tested. The GFP siRNA used as a nonspecific control in Example 1 was also used as a non-specific control here.

Twenty four hours after laser induction, one eye from each of eleven adult C57/Black6 mice (Jackson Labs, Bar Harbor, ME) was injected subretinally with a mixture containing  $\sim 1 \times 10^8$  particles of adenovirus containing LacZ driven by the CMV promoter and 20 picomoles of siRNA targeting mouse VEGF conjugated with transit TKO reagent (Mirus), as in Example 4. As a control, contralateral eyes received a mixture containing  $\sim 1 \times 10^8$  particles of adenovirus containing LacZ driven by the CMV promoter and 20 picomoles of siRNA targeting GFP conjugated with transit TKO reagent (Mirus).

Fourteen days after the laser treatment, the mice were perfused with fluorescein and the area of neovascularization was measured around the burn spots. Areas of the burn spots in the contra-lateral eye were used as a control. The site of neovascularization around the burn spots in animals that received siRNA targeting mouse VEGF was, on average, 1/4 the area of the control areas. These data support the use of VEGF-directed siRNA (also called "anti-VEGF siRNA") for therapy of ARMD.

#### **Example 7 - Generation of an Adeno-Associated Viral Vector for Expression of siRNA**

A "cis-acting" plasmid for generating a recombinant AAV vector for delivering an siRNA of the invention was generated by PCR based subcloning, essentially as described in Samulski R et al. (1987), *supra*. The cis-acting plasmid was called "pAAVsiRNA."

The *rep* and *cap* genes of psub201 were replaced with the following sequences in this order: a 19 nt sense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter, and a 19 nt antisense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter. A schematic representation of pAAVsiRNA is given in Fig. 5.

A recombinant AAV siRNA vector was obtained by transfecting pAAVsiRNA into human 293 cells previously infected with E1-deleted adenovirus, as described in Fisher KJ et al. (1996), *supra*. The AAV rep and cap functions were provided by a trans-acting plasmid pAAV/Ad as described in Samulski R et al. (1989), *supra*. Production lots of the recombinant AAV siRNA vector were titered according to the number of genome copies/ml, as described in Fisher KJ et al. (1996), *supra*.

**Example 8 – VEGF-Directed siRNA Inhibits Experimental Choroidal Neovascularization**

The ability of murine VEGF-directed siRNA to inhibit experimental laser-induced choroidal neovascularization (CNV) in mice was tested as follows.

The retinas of adult female C57BL/6 mice were laser photocoagulated using an 810 nm diode laser (75 um, 140 mw, 0.10 seconds) (OcuLight Six; IRIS Medical, Mountain View, CA). Three laser spots were applied to both eyes of each mouse. Thirty-six hours following laser photocoagulation, an siRNA targeted to mouse VEGF ("mVEGF1.siRNA") was delivered subretinally or intravitreally to one eye of each mouse. For subretinal injection, the siRNA was conjugated with Transit TKO transfection reagent (Mirus) and mixed with recombinant adenovirus (rAdenovirus). For intravitreal injection, the siRNA was delivered in the absence of transfection reagent and rAdenovirus. As a control, the contralateral eyes of each mouse received subretinal or intravitreal injections of identical formulations with an siRNA targeted to GFP ("GFP1.siRNA"), which has no homology to mouse VEGF.

Fourteen days following laser treatment, all animals were perfused with high molecular weight FITC-dextran, choroidal flat mounts were prepared as described above, and the flat mounts were photographed and analyzed microscopically in a masked fashion. The area of CNV in each flat mount was measured with Openlab software (Improvision, Boston, MA). The mean areas of CNV in eyes treated with mVEGF1.siRNA were significantly smaller than



those areas from GFP1.siRNA-treated eyes for both subretinal (Fig. 6A;  $P<0.003$ ) and intravitreal (Fig. 6B;  $P<0.04$ ) delivery.

In a second experiment, the retinas of adult female C57BL/6 mice were laser photocoagulated as described above, and the animals were divided into control and test groups. One day following laser photocoagulation, phosphate buffered saline was delivered intravitreally to the animals of the control group, which were perfused with dextran-fluorescein 14 days after laser treatment. Choroidal flat mounts were then prepared and the areas of CNV in each flat mount were measured as above.

Fourteen days following laser photocoagulation, mVEGF1.siRNA was delivered by intravitreal injection into one eye of each mouse in the test group. Contralateral eyes were injected with GFP1.siRNA as a control. The test group animals were perfused with high molecular weight dextran-fluorescein 21 days after laser treatment. Choroidal flat mounts were then prepared and the areas of CNV in each flat mount were measured, as above.

In this latter experiment, the anti-VEGF siRNA was administered during CNV growth, as opposed to before CNV growth, and thus is more representative of the condition of human patients presenting with wet AMD. As can be seen from Fig. 6, the mean areas of CNV in mVEGF1.siRNA-treated eyes were significantly smaller than those areas measured in GFP1.siRNA-treated eyes (Fig. 6C;  $P<0.05$ ). The mean areas of CNV in mVEGF1.siRNA-treated eyes at day 21 and control ("PBS") eyes at day 14 were not significantly different (Fig. 6C;  $P=0.469$ ).

The results of these experiments indicate that age-related macular degeneration can be treated with anti-VEGF siRNA.

#### **Example 9 – In Vivo RNA Interference of Human VEGF Induced by anti-VEGF siRNA in Murine RPE Cells**

The ability of Cand5 siRNA to induce RNAi of VEGF *in vivo* over time was evaluated as follows.

AAV.CMV.VEGF, which expresses human VEGF from an adeno-associated viral vector, was generously provided by Dr. A. Auricchio.

AAV.CMV.VEGF was injected subretinally and bilaterally in eyes of five C57Bl/6 mice. Twenty-eight days after injection of AAV.CMV.VEGF, Cand5 siRNA was delivered by intravitreal injection into one eye and control GFP1.siRNA was delivered by intravitreal injection in the contralateral eye of each animal.

At day 0 (pre-siRNA injection), and at 6, 10 and 14 days after siRNA injection, the mice were sacrificed and the eyes were snap frozen in liquid nitrogen following enucleation. The eyes were then homogenized in lysis buffer (Roche, Basel, Switzerland), and total protein was measured using a Bradford assay, as in Example 5 above. Two mice were used for the 0 day time point (n=2), and three mice each were used for the 6, 10 and 14 day time points (n=3). The samples were normalized for total protein prior to assaying for human VEGF by ELISA, according to the manufacturer's recommendations (R&D systems, Minneapolis, Minnesota). Percent of VEGF (%VEGF) for each mouse was calculated as the concentration of VEGF ("[VEGF]") in the eye injected with Cand5 divided by the [VEGF] in the eye injected with GFP1.siRNA, multiplied by 100.

As can be seen from Figure 7, a single injection of Cand5 induced an RNAi-mediated decrease in VEGF levels of approximately 70% by day 6 post-siRNA injection, with a reduction in VEGF production of approximately 35% continuing through at least day 14 post-siRNA injection. These results indicate that siRNA directed against human VEGF is capable of inducing RNAi of human VEGF *in vivo* for a sustained period of time.

#### **Example 10 – In Vivo RNA Interference of VEGF in Monkeys with Anti-VEGF siRNA**

It is expected that 10 naïve cynomolgus monkeys (*Macaca fascicularis*) will be subjected to laser photocoagulation of the retina in both eyes to induce choroidal neovascularization ("CNV"). The following represents the intended experimental plan to evaluate the ability of Cand5 siRNA to reduce the area of CNV in the monkeys. As the VEGF RNA sequence targeted by Cand5 is

identical in both *Homo sapiens* and *M. fascicularis*, Cand5 is expected to induce RNAi of *M. fascicularis* VEGF RNA.

The experiment will be carried out by Sierra Biomedical ("SBI"), 587 Dunn Circle, Sparks, NV, 89431, in accordance with SBI's Standard Operating  
5 Procedures. All monkeys will undergo a full pre-study health screen consisting of a physical examination, hematologic and ophthalmologic evaluations, serum chemistry, and electroretinography ("ERG"). A pre-study fluorescein angiography of the monkeys' eyes will also be performed, and intraocular pressure will be measured pre-study and at two additional time points during the  
10 study period.

On day zero, both eyes of all 10 monkeys will be laser photocoagulated to induce choroidal neovascularization. The animals will receive twice-daily cageside observations and a once-daily qualitative assessment of food consumption throughout the experiment. At 14 days post laser induction, the  
15 monkeys will receive intravitreally one 50 microliter dose of a Treatment or Control formulation (see below) in each eye, in a randomized, double-blind fashion. For example, a given animal could receive a Treatment 1 dose in the right eye, and a Control dose in the left eye. Another animal could receive a Treatment 1 dose in the right eye, and a Treatment 3 dose in the left eye. It is  
20 expected that four eyes will receive each formulation, for a total of 1 control and four treatment groups of four eyes each.

The formulations will be: Control - balanced saline solution ("BSS") alone; Treatment 1 - 1 mg/ml Cand5 in BSS; Treatment 2 - 2.5 mg/ml Cand5 in BSS; Treatment 3 - 5 mg/ml Cand5 in BSS; and Treatment 4 - 10 mg/ml Cand5  
25 in BSS. Prior to injection, it is expected that the pH, osmolarity, and the absorbance at 260 nm of each formulation will be measured.

After laser induction, a fluorescein angiography will be performed on both eyes of each monkey weekly up through the seventh week after laser induction. The monkeys will then be sacrificed, and a complete necropsy will  
30 be performed with a full tissue collection (~45 tissues including a vitreous sample) and histopathologic evaluation of the collected tissues. An ERG will be taken pre-necropsy.

It is expected that the laser-induced areas of CNV will be reduced upon administration of the Cand5 siRNA, with the CNV area decreasing with increasing dose of Can5. However, a plateau effect such as is described above in Example 2 may be observed. The Cand5 siRNA is not expected to effect any  
5 other organ or tissue except the choroid in the eye.

We claim:

1. An isolated siRNA comprising a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence of about 19 to about 25 contiguous nucleotides in human VEGF mRNA, human Flt-1 mRNA, or human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof.
2. The siRNA of claim 1, wherein the human VEGF mRNA is selected from the group consisting of VEGF<sub>121</sub> mRNA (SEQ ID NO: 2); VEGF<sub>165</sub> mRNA (SEQ ID NO: 3); VEGF<sub>189</sub> mRNA (SEQ ID NO: 4 ) and VEGF<sub>206</sub> mRNA (SEQ ID NO: 5).
3. The siRNA of claim 1, wherein the cognate of the human VEGF mRNA sequence is mouse VEGF mRNA (SEQ ID NO: 1).
4. The siRNA of claim 1, wherein the sense RNA strand comprises SEQ ID NO: 77, and the antisense strand comprises SEQ ID NO: 78.
5. The siRNA of claim 1, wherein the sense RNA strand comprises one RNA molecule, and the antisense RNA strand comprises one RNA molecule.
6. The siRNA of claim 1, wherein the sense and antisense RNA strands forming the RNA duplex are covalently linked by a single-stranded hairpin.
7. The siRNA of claim 1, wherein the siRNA further comprises non-nucleotide material.
8. The siRNA of claim 1, wherein the sense and antisense RNA strands are stabilized against nuclease degradation.

9. The siRNA of claim 1, further comprising a 3' overhang.
10. The siRNA of claim 9, wherein the 3' overhang comprises from 1 to about 6 nucleotides.
11. The siRNA of claim 9, wherein the 3' overhang comprises about 2 nucleotides.
12. The siRNA of claim 5, wherein the sense RNA strand comprises a first 3' overhang, and the antisense RNA strand comprises a second 3' overhang.
13. The siRNA of claim 12, wherein the first and second 3' overhangs separately comprise from 1 to about 6 nucleotides.
14. The siRNA of claim 13, wherein the first 3' overhang comprises a dinucleotide and the second 3' overhang comprises a dinucleotide.
15. The siRNA of claim 14, where the dinucleotide comprising the first and second 3' overhangs is dithymidylic acid (TT) or diuridylic acid (uu).
16. The siRNA of claim 9, wherein the 3' overhang is stabilized against nuclease degradation.
17. A retinal pigment epithelial cell comprising the siRNA of claim 1.
18. A recombinant plasmid comprising nucleic acid sequences for expressing an siRNA comprising a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence of about 19 to about 25 contiguous nucleotides in human VEGF mRNA, human Flt-1 mRNA, or human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof.

19. The recombinant plasmid of claim 18, wherein the nucleic acid sequences for expressing the siRNA comprise an inducible or regulatable promoter.

20. The recombinant plasmid of claim 18, wherein the nucleic acid sequences for expressing the siRNA comprise a sense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter, and an antisense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter.

21. The recombinant plasmid of claim 20, wherein the plasmid is pAAVsiRNA.

22. A recombinant viral vector comprising nucleic acid sequences for expressing an siRNA comprising a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence of about 19 to about 25 contiguous nucleotides in human VEGF mRNA, human Flt-1 mRNA, or human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof.

23. The recombinant viral vector of claim 22, wherein the nucleic acid sequences for expressing the siRNA comprise an inducible or regulatable promoter.

24. The recombinant viral vector of claim 22, wherein the nucleic acid sequences for expressing the siRNA comprise a sense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter, and an antisense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter.

25. The recombinant viral vector of claim 22, wherein the recombinant viral vector is selected from the group consisting of an adenoviral vector, an adeno-associated viral vector, a lentiviral vector, a retroviral vector, and a herpes virus vector.

26. The recombinant viral vector of claim 22, wherein the recombinant viral vector is pseudotyped with surface proteins from vesicular stomatitis virus, rabies virus, Ebola virus, or Mokola virus.

27. The recombinant viral vector of claim 25, wherein the recombinant viral vector comprises an adeno-associated viral vector.

28. A pharmaceutical composition comprising an siRNA and a pharmaceutically acceptable carrier, wherein the siRNA comprises a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence of about 19 to about 25 contiguous nucleotides in human VEGF mRNA, human Flt-1 mRNA, or human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof.

29. The pharmaceutical composition of claim 28, further comprising lipofectin, lipofectamine, cellfectin, polycations, or liposomes:

30. A pharmaceutical composition comprising the plasmid of claim 18, or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier.

31. The pharmaceutical composition of claim 30, further comprising lipofectin, lipofectamine, cellfectin, polycations, or liposomes.

32. A pharmaceutical composition comprising the viral vector of claim 22 and a pharmaceutically acceptable carrier.



33. A method of inhibiting expression of human VEGF mRNA, human Flt-1 mRNA, or human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof, comprising administering to a subject an effective amount of an siRNA comprising a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence of about 19 to about 25 contiguous nucleotides in human VEGF mRNA, human Flt-1 mRNA, or human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof, such that the human VEGF mRNA, human Flt-1 mRNA, or human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof, is degraded.

34. The method of claim 33, wherein the subject is a human being.

35. The method of claim 33, wherein expression of human VEGF mRNA, human Flt-1 mRNA, or human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof is inhibited in one or both eyes of the subject.

36. The method of claim 33, wherein expression of human VEGF mRNA, human Flt-1 mRNA, or human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof is inhibited in retinal pigment epithelial cells of the subject.

37. The method of claim 33, wherein the effective amount of the siRNA is from about 1 nM to about 100 nM.

38. The method of claim 33, wherein the siRNA is administered in conjunction with a delivery reagent.

39. The method of claim 38, wherein the delivery agent is selected from the group consisting of lipofectin, lipofectamine, cellfectin, polycations, and liposomes.

40. The method of claim 39, wherein the delivery agent is a liposome.

41. The method claim 40, wherein the liposome comprises a ligand which targets the liposome to cells at or near the site of angiogenesis.

42. The method of claim 41, wherein the ligand binds to receptors on tumor cells or vascular endothelial cells.

43. The method of claim 42, wherein the ligand comprises a monoclonal antibody.

44. The method of claim 40, wherein the liposome is modified with an opsonization-inhibition moiety.

45. The method of claim 44, wherein the opsonization-inhibiting moiety comprises a PEG, PPG, or derivatives thereof.

46. The method of claim 33, wherein the siRNA is expressed from a recombinant plasmid

47. The method of claim 33, wherein the siRNA is expressed from a recombinant viral vector.

48. The method of claim 47, wherein the recombinant viral vector comprises an adenoviral vector, an adeno-associated viral vector, a lentiviral vector, a retroviral vector, or a herpes virus vector.

49. The method of claim 48, wherein the recombinant viral vector is pseudotyped with surface proteins from vesicular stomatitis virus, rabies virus, Ebola virus, or Mokola virus.

50. The method of claim 47, wherein the recombinant viral vector comprises an adeno-associated viral vector.

51. The method of claim 33, wherein the siRNA is administered by an enteral administration route.

52. The method of claim 51, wherein the enteral administration route is selected from the group consisting of oral, rectal, and intranasal.

53. The method of claim 33, wherein the siRNA is administered by a parenteral administration route.

54. The method of claim 53, wherein the parenteral administration route is selected from the group consisting of intravascular administration, peri- and intra-tissue administration, subcutaneous injection or deposition, subcutaneous infusion, intraocular administration, and direct application at or near the site of neovascularization.

55. The method of claim 54, wherein the intravascular administration is selected from the group consisting of intravenous bolus injection, intravenous infusion, intra-arterial bolus injection, intra-arterial infusion and catheter instillation into the vasculature.

56. The method of claim 54, wherein the peri- and intra-tissue injection comprises peri-tumoral injection or intra-tumoral injection.

57. The method of claim 54, wherein the intraocular administration comprises intravitreal, intraretinal, subretinal, subtenon, peri- and retro-orbital, trans-corneal or trans-scleral administration.

58. The method of claim 54, wherein the direct application at or near the site of neovascularization comprises application by catheter, corneal pellet, eye dropper, suppository, an implant comprising a porous material, an implant comprising a non-porous material, or an implant comprising a gelatinous material.

59. The method of claim 54, wherein the site of neovascularization is in the eye, and the direct application at or near the site of neovascularization comprises application by an ocular implant.

60. The method of claim 59, wherein the ocular implant is biodegradable.

61. A method of inhibiting angiogenesis in a subject, comprising administering to a subject an effective amount of an siRNA comprising a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence of about 19 to about 25 contiguous nucleotides in human VEGF mRNA, human Flt-1 mRNA, or human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof.

62. The method of claim 61, wherein the angiogenesis is pathogenic.

63. The method of claim 61, wherein the angiogenesis is non-pathogenic.

64. The method of claim 63, wherein the non-pathogenic angiogenesis is associated with production of fatty tissues or cholesterol production.

65. The method of claim 63, wherein the non-pathogenic angiogenesis comprises endometrial neovascularization.

66. The method of claim 61, wherein the angiogenesis is inhibited in one or both eyes of the subject.

67. The method of claim 61, wherein the angiogenesis is inhibited in retinal pigment epithelial cells of the subject.

68. A method of treating an angiogenic disease in a subject, comprising administering to a subject in need of such treatment an effective amount of an siRNA comprising a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence of about 19 to about 25 contiguous nucleotides in human VEGF mRNA, human Flt-1 mRNA, or human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof, such that angiogenesis associated with the angiogenic disease is inhibited.

69. The method of claim 68, wherein the angiogenic disease comprises a tumor associated with a cancer.

70. The method of claim 69, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, head and neck cancer, brain cancer, abdominal cancer, colon cancer, colorectal cancer, esophagus cancer, gastrointestinal cancer, glioma, liver cancer, tongue cancer, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, Wilm's tumor, multiple myeloma, skin cancer, lymphoma, and blood cancer.

71. The method of claim 68, wherein the angiogenic disease is selected from the group consisting of diabetic retinopathy, age-related macular degeneration, and inflammatory diseases.

72. The method of claim 71, wherein the inflammatory disease is psoriasis or rheumatoid arthritis.

73. The method of claim 71, wherein the angiogenic disease is age-related macular degeneration.

74. The method of claim 68, wherein the siRNA is administered in combination with a pharmaceutical agent for treating the angiogenic disease, which pharmaceutical agent is different from the siRNA.

75. The method of claim 74, wherein the angiogenic disease is cancer, and the pharmaceutical agent comprises a chemotherapeutic agent.

76. The method of claim 74, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, cyclophosphamide, 5-fluorouracil, adriamycin, daunorubicin, and tamoxifen.

77. The method of claim 68, wherein the siRNA is administered to a subject in combination with another therapeutic method designed to treat the angiogenic disease.

78. The method of claim 77, wherein the angiogenic disease is cancer, and the siRNA is administered in combination with radiation therapy, chemotherapy or surgery.

1/8




FIG. 1A




FIG. 1B

2/8




FIG. 2



3/8




FIG. 3

4/8




FIG. 4

5/8




FIG. 5

6/8




FIG. 6A




FIG. 6B

7/8




FIG. 6C

8/8




FIG. 7

## SEQUENCE LISTING

<110> The Trustees of the University of Pennsylvania  
 Tolentino, Michael J.  
 Reich, Samuel Jotham

<120> Compositions and Methods for siRNA  
 Inhibition of Angiogenesis

<130> 43826-1 PC

<150> US 60/398,417

<151> 2002-07-24

<150> US 10/294,228

<151> 2002-11-14

<160> 864

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2250

<212> DNA

<213> Mus musculus

<400> 1

```

tgagccaggc tggcaggaag gagcctccct cagggtttcg ggaaccagac ctctcaccgg 60
aaagaccgat taaccatgtc accaccacgc catcatcgtc accgttgaca gaacagtcct 120
taatccagaa agcctgacat gaaggaagag gagactcttc gaggagcact ttgggtccgg 180
agggcgagac tccggcagac gcattcccg gagggtgacc aagcacggtc cctcgtggga 240
ctggattcgc cttttcttta tatctgctgc taaatcgcca agcccggaa attaggggtg 300
tttctgggat tcctgtagac acaccacccc acatacacac atatataat attatata 360
taaataaata tatatgtttt atatataaaa tatatatata ttcttttttt taaattaact 420
ctgctaattgt tattggtgtc ttcaactgat atgtttgact gctgtggact tgtgttggga 480
ggaggatgtc ctcaactcga tgcgcacatg ggagacaatg ggatgaaagg cttcagtgtg 540
gtctgagaga ggccgaagtc cttttgcctg ccggggagca agcaaggcca gggcacgggg 600
gcacattggc tcacttccag aaacacgaca aaccattcc tggccctgag tcaagaggac 660
agagagacag atgatgacac agaaagagat aaagatgccg gttccaacca gaagtttggg 720
gagcctcagg acatggcatg ctttgtggat ccccatgata gtctacaaaa gcaccccgcc 780
cctctgggca ctgcctggaa gaatcgggag cctggccagc cttcagctcg ctcctccact 840
tctgaggggc ctaggaggcc tcccacaggt gtcccggcaa gagaagacac ggtggtggaa 900
gaagaggcct ggtaatggcc cctcctcctg ggacccttc gtccctcctc taccacacct 960
cctgggtaca gcccaggagg accttgtgtg atcagaccat tgaaaccact aattctgtcc 1020
ccaggagact tggctctgtg tgtgagtggc ttacccttcc tcatcttccc ttcccaaggc 1080
acagagcaat ggggcaggac ccgcaagccc ctcacggagg cagagaaaag agaaagtgtt 1140
ttatatacgg tacttattta atagcccttt ttaattagaa attaaaacag ttaatttaat 1200
taaagagtag ggtttttttc agtattcttg gttaattatt aatttcaact atttatgaga 1260
tgtatctctc gctctctctt atttgactt atgtgtgtgt gtgtgtgtgt gtgtgtgtgt 1320
gtgtgtgtgt gtatgaaatc tgtgtttcca atctctctct cccagatcgg tgacagtcac 1380
tagcttgtcc tgagaagata tttaattttg ctaacactca gctctgccct cccttgtccc 1440
caccacacat tcctttgaaa taagggtttca atatacattt acatactata tatatatttg 1500
gcaacttgtg tttgtatata aatatatata tatatatatg tttatgtata tatgtgattc 1560
tgataaaaata gacattgcta ttctgttttt tatatgtaaa aacaaaacaa gaaaaataga 1620
gaattctaca tactaaatct ctctcctttt ttaattttta ttttgttat catttattta 1680
ttgggtgctac tgtttatccg taataattgt gggggaaaaa gatattaaca tcacgtcttt 1740
gtctctagag cagttttccg agatattccg tagtacatat ttatttttaa acagcaacaa 1800
agaaatacag atatatctta aaaaaaagc attttgtatt aaagaattga attctgatct 1860

```

```

caaagctctc cctgggtctct ccttctctcc tgggccctcc tgtctcgctt tccctcctcc 1920
tttggggtac atagtttttg tcttaggttt gagaagcagt ccctggagta gaatatgggg 1980
tgacccatcc attcctgggc ggaggggaga tggctccttt gccaaagggtc ctcacactac 2040
gtggtactct gttccttgct agacaaggat gggggcatgt ctccagggtc taactggaga 2100
tcggagagag ctgttggctg cagctggcca ggatttgggc atgccgggga catgggaggc 2160
tgtgagccca gcatgcagtt tacttctggg tgctaaatgg aagagtccag taaaaagagt 2220
cttgcccatg ggattccatt ccgctttgtg 2250

```

&lt;210&gt; 2

&lt;211&gt; 444

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

atgaactttc tgctgtcttg ggtgcattgg agccttgccct tgctgctcta cctccaccat 60
gccaaagtggc cccaggctgc acccatggca gaaggaggag ggcagaatca tcacgaagtg 120
gtgaagtcca tggatgtcta tcagcgcagc tactgccatc caatcgagac cctggtggac 180
atcttccagg agtaccctga tgagatcgag tacatcttca agccatcctg tgtgcccctg 240
atgcatgacg ggggctgctg caatgacgag ggcctggagt gtgtgcccac tgaggagtcc 300
aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg 360
agcttcttac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa 420
aatgtgtaca agccgagggc gtga 444

```

&lt;210&gt; 3

&lt;211&gt; 576

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

```

atgaactttc tgctgtcttg ggtgcattgg agccttgccct tgctgctcta cctccaccat 60
gccaaagtggc cccaggctgc acccatggca gaaggaggag ggcagaatca tcacgaagtg 120
gtgaagtcca tggatgtcta tcagcgcagc tactgccatc caatcgagac cctggtggac 180
atcttccagg agtaccctga tgagatcgag tacatcttca agccatcctg tgtgcccctg 240
atgcatgacg ggggctgctg caatgacgag ggcctggagt gtgtgcccac tgaggagtcc 300
aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg 360
agcttcttac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa 420
aatcctgtg ggccttgctc agagcggaga aagcatttgt ttgtacaaga tccgcagacg 480
tgtaaatgtt cctgcaaaaa cacagactcg cgttgcaagg cgaggcagct tgagttaaac 540
gaacgtactt gcagatgtga caagccgagg cgggtga 576

```

&lt;210&gt; 4

&lt;211&gt; 648

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

```

atgaactttc tgctgtcttg ggtgcattgg agccttgccct tgctgctcta cctccaccat 60
gccaaagtggc cccaggctgc acccatggca gaaggaggag ggcagaatca tcacgaagtg 120
gtgaagtcca tggatgtcta tcagcgcagc tactgccatc caatcgagac cctggtggac 180
atcttccagg agtaccctga tgagatcgag tacatcttca agccatcctg tgtgcccctg 240
atgcatgacg ggggctgctg caatgacgag ggcctggagt gtgtgcccac tgaggagtcc 300
aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg 360
agcttcttac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa 420
aaaaaatcag ttcgaggaaa gggaaagggg caaaaacgaa agcgcaagaa atccccgtat 480
aagtcctgga gcgttccttg tgggccttgc tcagagcgga gaaagcattt gtttgtacaa 540
gatccgcaga cgtgtaaatg ttccctgcaa aacacagact cgcgttgcaa ggcgaggcag 600
cttgagttaa acgaacgtac ttgcagatgt gacaagccga ggcggtga 648

```

&lt;210&gt; 5

&lt;211&gt; 670

&lt;212&gt; DNA



&lt;213&gt; Homo sapiens

&lt;400&gt; 5

```

gccttgctgc tctacctcca ccatgccaaag tgggtcccagg ctgcacccat ggcagaagga 60
ggagggcaga atcatcacga agtgggtgaag ttcattgatg tctatcagcg cagctactgc 120
catccaatcg agaccctggg ggacatcttc caggagtacc ctgatgagat cgagtacatc 180
ttcaagccat cctgtgtgcc cctgatgcga tgcggggggt gctgcaatga cgagggcctg 240
gagtgtgtgc ccactgagga gtccaacatc accatgcaga ttatgcggat caaacctcac 300
caaggccagc acataggaga gatgagcttc ctacagcaca acaaatgtga atgcagacca 360
aagaaggata gagcaagaca agaaaaaaaa tcaattcgag gaaagggaaa ggggcaaaaa 420
cgaaagcgca agaaatcccg gtataagtcc tggagcggtt acgttgggtg ccgctgctgt 480
ctaagccctt ggagcctccc tggcccccct ccctgtgggc cttgctcaga gcggagaaag 540
catttgtttg tacaagatcc gcagacgtgt aaatgttccg gcaaaaacac agactcgcgt 600
tgcaaggcga ggcagcttga gttaaacgaa cgtacttgca gatgtgacaa gccgaggcgg 660
tgatgaatga                                     670

```

&lt;210&gt; 6

&lt;211&gt; 1137

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

```

atgctcattg tccagactgg ggtcagatca gcaaacaag ggcctctgat ggtgattgtt 60
gaatattgca aatatggaaa tctatccaac tacctcaaga gcaaatatga cttatttttt 120
ctcgacaagg atgtggcatc acacatggag cgtaagaaag aaaaaatgga gccaggcctg 180
gaacaaggca agaaacccaa actagatagc atcaccagca gcgagagctt tgggagctcc 240
aagtttcagg aagataaaaa tctgagtgat gttgaggaag aggaggattc tgatgggttc 300
taccaggagc ccatcactat ggaagatctg atttcttaca gttttcaagt ggccagaggc 360
atgaagtttc tgtcttccag aaagtgcatt cattgggacc tggcagcaag aaacattctt 420
ttatctgaga acaatgtggg gaagatttgt gattttggcc ttgcccagga tatttacaag 480
aacgccgatt atgtgagaaa aggaggtggg tctccatacc caggagtgcg aatggatgag 540
cacttctgca gttgcctgag ggaaggcatg aggatgagag ctgctgagta ctccactcct 600
gaaatctatc agatcatgct ggactgcagg cacaagacc caaaagaaa gccaagattt 660
gcagaacttg tggaaaaaact agaaaatagt gggtttacat actcaactcc tgccttctct 720
gaggacttct tcaaggaagg tatttcagct cccaagttaa gttcaggaag ctctgatgat 780
gtcagatacg taaatgcttt caagttcatg agcctggaaa gaatcaaac ctttgagaa 840
cttttgccaa atgccacctc catgtttgat gactaccagg gggacagcag cgctctgctg 900
gcctctccca tgcgtgaagc cttcaccagg actgacagca aacccaaggc ctgcgtcaag 960
attgacttga gactaactag caaaagtaag aagtcggggc tttctgatgt cagcaggccc 1020
agtttctgcc attccaacag tgggcacatc agcaaggcga agggcagggt cacctacgac 1080
aacgccgagc tggaaaggaa gacggcgtgc tgcctccgcg ccctctggga gttgtag 1137

```

&lt;210&gt; 7

&lt;211&gt; 5830

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

```

actgagtcce gggaccccg gagagcggtc agtgtgtggt cgctgcgttt cctctgcctg 60
cgccgggcat cacttgccgc ccgcagaaag tccgtctggc agcctggata tcctctccta 120
ccggcaccgc cagacgcccc tgcagccgcc ggtcgccgcc cgggctccct agccctgtgc 180
gctcaactgt cctgcgctgc ggggtgccgc gagtccacc tccgcgcctc cttctctaga 240
caggcgctgg gagaaagaac cggtcccgga gttctgggca tttcgcccgc ctcgaggtgc 300
aggatgcaga gcaagggtgt gctggccgtc gccctgtggc tctgcgtgga gacccgggcc 360
gcctctgtgg gtttgccctag tgtttctctt gatctgccc ggcctcagcat acaaaaagac 420
atacttaca ttaaggctaa tacaactctt caaattactt gcaggggaca gagggacttg 480
gactggcttt ggcccaataa tcagagtggc agtgagcaaa ggggtggagg gactgagtgc 540
agcgatggcc tcttctgtaa gacactcaca attccaaaag tgatcggaat tgacactgga 600
gcctacaagt gcttctaccg ggaaactgac ttggcctcgg tcatthtatgt ctatgttcaa 660
gattacagat ctccatttat tgcttctgtt agtgaccaac atggagtcgt gtacattact 720
gagaacaaaa acaaaaactgt ggtgattcca tgtctcgggt ccatttcaaa tctcaacgtg 780

```

tcactttgtg caagataccc agaaaagaga tttgttcttg atggtaacag aatttccttg 840  
 gacagcaaga agggctttac tattcccagc tacatgatca gctatgctgg catggctctc 900  
 tgtgaagcaa aaattaatga tgaaagttac cagtctatta tgtacatagt tgtcgttgta 960  
 gggatatagga tttatgatgt ggttctgagt ccgtctcatg gaattgaact atctgttga 1020  
 gaaaagcttg tcttaaattg tacagcaaga actgaactaa atgtggggat tgacttcaac 1080  
 tgggaatacc cttcttcgaa gcatcagcat aagaaacttg taaaccgaga cctaaaaacc 1140  
 cagtctggga gtgagatgaa gaaatttttg agcaccttaa ctatagatgg tgaacccgg 1200  
 agtgaccaag gattgtacac ctgtgcagca tccagtgggc tgatgaccac gaagaacagc 1260  
 acatttgtca gggccatga aaaacctttt gttgcttttg gaagtggcat ggaatctctg 1320  
 gtggaagcca cgggtgggga gcgtgtcaga atccctgcga agtaccttgg ttaccacacc 1380  
 ccagaaataa aatggtataa aaatggaata ccccttgagt ccaatcacac aattaaagcg 1440  
 gggcatgtac tgacgattat ggaagtgagt gaaagagaca caggaaatta cactgtcatc 1500  
 cttaccaatc ccatttcaaa ggagaagcag agccatgtgg tctctctggt tgtgtatgtc 1560  
 ccaccccaga ttggtgagaa atctctaatc tctctgtgg attcctacca gtacggcac 1620  
 actcaaaccg tgacatgtac ggtctatgcc attcctccoc cgcatcacat ccactggtat 1680  
 tggcagttgg aggaagagtg cgcaacagag cccagccaag ctgtctcagt gacaaacca 1740  
 tacccttgtg aagaatggag aagtgtggag gacttccagg gaggaaataa aattgaagt 1800  
 aataaaaaatc aatttgcctc aattgaagga aaaaacaaa ctgtaagtac ccttggtatc 1860  
 caagcggcaa atgtgtcagc tttgtacaaa tgtgaagcgg tcaacaaagt cgggagagga 1920  
 gagagggtga tctcctcca cgtgaccagg ggtcctgaaa ttactttgca acctgacatg 1980  
 cagcccactg agcaggagag cgtgtctttg tgggtcactg cagacagatc tacgtttgag 2040  
 aacctcacat ggtacaagct tggcccacag cctctgccaa tccatgtggg agagttgcc 2100  
 acacctgttt gcaagaactt ggatactctt tggaaattga atgccaccat gttctcta 2160  
 agcacaaatg acattttgat catggagctt aagaatgcat ccttcagga ccaaggagac 2220  
 tatgtctgcc ttgctcaaga caggaaagac aagaaaagac attgcgtggt caggcagctc 2280  
 acagtcctag agcgtgtggc acccacgatc acaggaaacc tggagaatca gacgacaagt 2340  
 attggggaaa gcatcgaagt ctcatgcacg gcatctggga atccccctcc acagatcatg 2400  
 tggtttaaaag ataatgagac cctttagaa gactcaggca ttgtattgaa ggtgggaac 2460  
 cggaacctca ctatccgag agtgaggaag gaggacgaag gcctctacac ctgccaggca 2520  
 tgcagtgttc ttggctgtgc aaaagtggag gcattttca taatagaagg tgcccaggaa 2580  
 aagacgaact tggaaatcat tattctagta ggacggcgg tgattgccat gttcttctg 2640  
 ctacttcttg tcatcatcct acggaccgtt aagcgggcca atggaggga actgaagaca 2700  
 ggctacttgt ccactgcat ggatccagat gaactccat tggatgaaca ttgtgaacga 2760  
 ctgcttatg atgccagcaa atgggaatc cccagagacc ggctgaagct aggtaaacct 2820  
 cttggcogtg gtgcctttg ccaagtgatt gaagcagatg cctttggaat tgacaagaca 2880  
 gcaacttgca ggacagtagc agtcaaaatg ttgaaagaag gagcaacaca cagtgaagcat 2940  
 cgagctctca tgtctgaact caagatcctc attcatattg gtcaccatct caatgtggtc 3000  
 aaccttctag gtgcctgtac caagccagga gggccactca tgggtattgt ggaattctgc 3060  
 aaatttggaa acctgtccac ttacctgagg agcaagagaa atgaatttgt cccctacaag 3120  
 accaaagggg cagcattccg tcaaggga gactacgttg gagcaatccc tgtggatctg 3180  
 aaacggcgct tggacagcat caccagtagc cagagctcag ccagctctgg atttgtggag 3240  
 gagaagtccc tcagtgatgt agaagaagag gaagctcctg aagatctgta taaggacttc 3300  
 ctgaccttgg agcatctcat ctgttacagc ttccaagtgg ctaagggcat ggagtcttg 3360  
 gcatcgcgaa agtgtatcca caggacctg gcggcacgaa atatcctctt atcgagaag 3420  
 aacgtggtta aaatctgtga ctttggcttg gccgggata tttataaaga tccagattat 3480  
 gtcagaaaag gagatgctcg cctcccttg aaatggatgg cccagaaac aatttttgac 3540  
 agagtgtaca caatccagag tgacgtctgg tcttttggg ttttgcgtg ggaaatatt 3600  
 tccttaggtg cttctccata tcctgggta aagattgatg aagaattttg taggcgattg 3660  
 aaagaaggaa ctagaatgag gggccctgat tatactacac cagaaatgta ccagaccatg 3720  
 ctggactgct ggcacgggga gccagtcag agaccacgt tttcagagt ggtggaacat 3780  
 ttgggaaatc tcttgcaagc taatgctcag caggatggca aagactacat tgttctccg 3840  
 atatcagaga ctttgagcat ggaagagat tctggactct ctctgcctac ctacctgtt 3900  
 tcctgtatgg aggaggagga agtatgtgac cccaaattcc attatgacaa cacagcagga 3960  
 atcagtcagt atctgcagaa cagtaagcga aagagccggc ctgtgagtg aaaaacattt 4020  
 gaagatatcc cgttagaaga accagaagta aaagtaatcc cagatgacaa ccagacggac 4080  
 agtggatagg ttcttgccctc agaagagctg aaaacttttg aagacagaac caaattatct 4140  
 ccactctttg gtggaatggt gccagcaaa agcaggagat ctgtggcatc tgaaggctca 4200  
 aaccagacaa gcgctacca gtccgatat cactccgatg acacagacac caccgtgtac 4260  
 tccagtggg aggcagaact tttaaagctg atagagattg gagtgcacaa cggtagcaca 4320  
 gccagattc tccagcctga ctccgggacc acactgagct ctctcctgt ttaaaaggaa 4380  
 gcatccacac cccaactccc ggacatcaca tgagaggtct gctcagattt tgaagtgtt 4440

```

ttctttccac cagcaggaag tagccgcatt tgattttcat ttcgacaaca gaaaaaggac 4500
ctcggactgc agggagccag tcttctaggc atatcctgga agaggcttgt gacccaagaa 4560
tgtgtctgtg tcttctccca gtgttgacct gatcctcttt tttcattcat ttaaaaagca 4620
ttatcatgcc cctgctgcgg gtctcaccat gggtttagaa caaagagctt caagcaatgg 4680
ccccatcctc aaagaagtag cagtacctgg ggagctgaca cttctgtaaa actagaagat 4740
aaaccaggca acgtaagtgt tcgaggtggt gaagatggga aggatttgca gggctgagtc 4800
tatccaagag gctttgttta ggacgtgggt cccaagccaa gccttaagtg tggaattcgg 4860
attgatagaa aggaagacta acgttacctt gctttggaga gtactggagc ctgcáaatgc 4920
attgtgtttg ctctgggtga ggtgggcatg gggctctgtc tgaaatgtaa agggttcaga 4980
cggggtttct ggtttttagaa ggttgctgtt tcttcgagtt gggctaaagt agagtctggt 5040
gtgctgtttc tgactcctaa tgagagttcc ttccagaccg ttagctgtct ccttgccaag 5100
ccccaggaag aaaatgatgc agctctggct ccttgtctcc caggctgatc ctttattcag 5160
aataccacaa agaaaggaca ttcagctcaa ggctccctgc cgtggtgaag agttctgact 5220
gcacaaacca gcttctggtt tcttctggaa tgaataccct catatctgtc ctgatgtgat 5280
atgtctgaga ctgaatgcgg gaggttcaat gtgaagctgt gtgtgggtgc aaagtttcag 5340
gaaggatttt acccttttgt tcttccccct gtccccaacc cactctcacc ccgcaaccca 5400
tcagtatttt agttatttgg cctctactcc agtaaacctg attgggtttg ttcactctct 5460
gaatgattat tagccagact tcaaaattat tttatagccc aaattataac atctattgta 5520
ttatttagac ttttaacata tagagctatt tctactgatt tttgcccttg ttctgtcctt 5580
tttttcaaaa aagaaaatgt gttttttgtt tggtagcata gtgtgaaatg ctgggaacaa 5640
tgactataag acatgctatg gcacatatat ttatagtctg tttatgtaga aacaaatgta 5700
atatattaaa gccttatata taatgaactt tgtactattc acattttgta tcagtattat 5760
gtagcataac aaaggtcata atgctttcag caattgatgt cattttatta aagaacattg 5820
aaaaacttga                                     5830

```

&lt;210&gt; 8

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 8

tcatcacgaa gtggtgaag

19

&lt;210&gt; 9

&lt;211&gt; 21

&lt;212&gt; RNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 9

ucaucacgaa guggugaagu u

21

&lt;210&gt; 10

&lt;211&gt; 21

&lt;212&gt; RNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 10

cuucaccacu ucgugaugau u

21

&lt;210&gt; 11

&lt;211&gt; 21

&lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<221> misc\_RNA

<222> (1)...(19)

<223> ribonucleotide

<221> misc\_feature

<222> (20)...(21)

<223> deoxyribonucleotide

<400> 11

ucaucacgaa guggugaagt t

21

<210> 12

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<221> misc\_RNA

<222> (1)...(19)

<223> ribonucleotides

<221> misc\_feature

<222> (20)...(21)

<223> deoxyribonucleotides

<400> 12

cuucaccacu ucgugaugat t

21

<210> 13

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 13

aacgtacttg cagatgtgac a

21

<210> 14

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 14

gttcatggat gtctatcag

19

<210> 15

<211> 19

<212> DNA

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 15

tcgagaccct ggtggacat

19

&lt;210&gt; 16

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 16

tgacgagggc ctggagtgt

19

&lt;210&gt; 17

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 17

tgacgagggc ctggagtgt

19

&lt;210&gt; 18

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 18

catcaccatg cagattatg

19

&lt;210&gt; 19

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 19

acctcaccaa ggccagcac

19

&lt;210&gt; 20

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 20

ggccagcaca taggagaga

19

<210> 21  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 21  
caaatgtgaa tgcagacca 19

<210> 22  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 22  
atgtgaatgc agaccaaag 19

<210> 23  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 23  
tgcagaccaa agaaagata 19

<210> 24  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 24  
agaaagatag agcaagaca 19

<210> 25  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 25  
gaaagataga gcaagacaa 19

<210> 26  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 26  
gatagagcaa gacaagaaa 19

<210> 27  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 27  
gacaagaaaa tccctgtgg 19

<210> 28  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 28  
gaaaatccct gtgggcctt 19

<210> 29  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 29  
aatccctgtg ggccttgct 19

<210> 30  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 30  
tccctgtggg ccttgctca 19

<210> 31  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 31  
gcatttgttt gtacaagat 19

<210> 32  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 32  
gatccgcaga cgtgtaaatt 19

<210> 33  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 33  
atgttcctgc aaaaacaca 19

<210> 34  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 34  
tggttcctgca aaaacacag 19

<210> 35  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 35  
aaacacagac tcgcgttgcc 19

<210> 36  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 36  
aacacagact cgcgttgcca 19

<210> 37  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>



<223> Targeting sequence

<400> 37

acacagactc gcgttgcaa

19

<210> 38

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 38

cacagactcg cggttgcaag

19

<210> 39

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 39

ggcgaggcag cttgagtta

19

<210> 40

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 40

acgaacgtac ttgcagatg

19

<210> 41

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 41

cgaacgtact tgcagatgt

19

<210> 42

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 42

cgtacttgca gatgtgaca

19

<210> 43

<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 43  
gtggtcccag gctgcaccc 19

<210> 44  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 44  
ggaggagggc agaatcatc 19

<210> 45  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 45  
gtggtgaagt tcatggatg 19

<210> 46  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 46  
aatcatcacg aagtggtgaa g 21

<210> 47  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 47  
aagttcatgg atgtctatca g 21

<210> 48  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 48  
aatcgagacc ctggtggaca t 21

<210> 49  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 49  
aatgacgagg gcctggagtg t 21

<210> 50  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 50  
aacatcacca tgcagattat g 21

<210> 51  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 51  
aaacctcacc aaggccagca c 21

<210> 52  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 52  
aaggccagca cataggagag a 21

<210> 53  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 53  
aacaatgtg aatgcagacc a 21

<210> 54  
<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 54  
aaatgtgaat gcagaccaa g 21

<210> 55  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 55  
aatgcagacc aaagaaagat a 21

<210> 56  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 56  
aaagaaagat agagcaagac a 21

<210> 57  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 57  
aagaaagata gagcaagaca a 21

<210> 58  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 58  
aagatagagc aagacaagaa aat 23

<210> 59  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 59  
aagacaagaa aatccctgtg ggc 23

<210> 60  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 60  
aagaaaatcc ctgtgggcct tgc 23

<210> 61  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 61  
aatccctgtg ggccttgctc aga 23

<210> 62  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 62  
aagcatttgt ttgtacaaga tcc 23

<210> 63  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 63  
aagatccgca gacgtgtaaa tgt 23

<210> 64  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 64  
aaatgttcct gcaaaaacac aga 23

<210> 65  
<211> 23  
<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 65

aatgttcctg caaaaacaca gac

23

<210> 66

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 66

aaaaacacag actcgcgttg caa

23

<210> 67

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 67

aaaacacaga ctgcggttgc aag

23

<210> 68

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 68

aaacacagac tcgcgttgca agg

23

<210> 69

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 69

aacacagact cgcgttgcaa ggc

23

<210> 70

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 70

aaggcgaggc agcttgagtt aaa 23

<210> 71  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 71  
aaacgaacgt acttgacgat gtg 23

<210> 72  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 72  
aacgaacgta cttgcagatg tga 23

<210> 73  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 73  
aagtgggtccc aggtgcacc cat 23

<210> 74  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 74  
aaggaggagg gcagaatcat cac 23

<210> 75  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 75  
aagtggtgaa gttcatggat gtc 23

<210> 76  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence  
  
<400> 76  
aaaatccctg tgggccttgc tca

23

<210> 77  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<221> misc\_RNA  
<222> (1)...(19)  
<223> ribonucleotides

<221> misc\_feature  
<222> (20)...(21)  
<223> deoxyribonucleotides

<400> 77  
accucaccaa ggccagcact t

21

<210> 78  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<221> misc\_RNA  
<222> (1)...(19)  
<223> ribonucleotides

<221> misc\_feature  
<222> (20)...(21)  
<223> deoxyribonucleotides

<400> 78  
gugcuggccu uggugaggut t

21

<210> 79  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 79  
ggctacgtcc agcgcacc

18

<210> 80  
<211> 21  
<212> DNA  
<213> Artificial Sequence



<220>  
<223> Targeting sequence

<400> 80  
aaaccucacc aaagccagca c 21

<210> 81  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 81  
ggcagaatca tcacgaagtg g 21

<210> 82  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 82  
cctggtggac atcttcagg a 21

<210> 83  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 83  
gagatcgagt acatcttcaa g 21

<210> 84  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 84  
tggagtgtgt gccactgag g 21

<210> 85  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 85  
gagcttccta cagcacaaca a 21

<210> 86  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 86  
ttgctcagag cggagaaaagc a 21

<210> 87  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 87  
cacacactcg cgttgcaagg c 21

<210> 88  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 88  
tcaccatgca gattatgcgg a 21

<210> 89  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 89  
tagagcaaga caagaaaatc c 21

<210> 90  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 90  
ccgcagacgt gtaaattgttc c 21

<210> 91  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 91

aagcaggcca gacactgcat c

21

<210> 92

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 92

aatgcagggg ggaagcagcc c

21

<210> 93

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 93

aagcagccca taaatggtct t

21

<210> 94

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 94

aaatggtctt tgcttgaaat g

21

<210> 95

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 95

aatggtcttt gcctgaaatg g

21

<210> 96

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 96

aatggtgag taaggaaagc g

21

<210> 97

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 97  
aatggtgagt aaggaaagcg a 21

<210> 98  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 98  
aaggaaagcg aaaggctgag c 21

<210> 99  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 99  
aaagcgaaag gctgagcata a 21

<210> 100  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 100  
aagcgaaagg ctgagcataa c 21

<210> 101  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 101  
aaaggctgag cataactaaa t 21

<210> 102  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 102  
aaggctgagc ataactaaat c 21

<210> 103  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 103  
aactaaatct gcctgtggaa g 21

<210> 104  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 104  
aaatctgcct gtggaagaaa t 21

<210> 105  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 105  
aatctgcctg tggaagaaat g 21

<210> 106  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 106  
aagaaatggc aaacaattct g 21

<210> 107  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 107  
aatggcaaa caattctgca g 21

<210> 108  
<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 108  
aatggcaaac aattctgcag t 21

<210> 109  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 109  
aaacaattct gcagtacttt a 21

<210> 110  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 110  
aacaattctg cagtacttta a 21

<210> 111  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 111  
aattctgcag tactttaacc t 21

<210> 112  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 112  
aaccttgaac acagctcaag c 21

<210> 113  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 113  
aacacagctc aagcaaacca c 21

<210> 114  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 114  
aagcaaacca cactggcttc t 21

<210> 115  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 115  
aaaccacact ggcttctaca g 21

<210> 116  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 116  
aaccacactg gcttctacag c 21

<210> 117  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 117  
aaatatctag ctgtacctac t 21

<210> 118  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 118  
aatatctagc tgtacctact t 21

<210> 119  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 119

aaagaagaag gaaacagaat c

21

<210> 120

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 120

aagaagaagg aaacagaatc t

21

<210> 121

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 121

aagaaggaaa cagaatctgc a

21

<210> 122

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 122

aaggaaacag aatctgcaat c

21

<210> 123

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 123

aaacagaatc tgcaatctat a

21

<210> 124

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 124



aacagaatct gcaatctata t 21

<210> 125  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 125  
aatctgcaat ctatatattt a 21

<210> 126  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 126  
aatctatata tttattagt a 21

<210> 127  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 127  
aaatccccga aattatacac a 21

<210> 128  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 128  
aatccccgaa attatacaca t 21

<210> 129  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 129  
aaattataca catgactgaa g 21

<210> 130  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 130  
aattatacac atgactgaag g 21

<210> 131  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 131  
aaggaagggga gctcgtcatt c 21

<210> 132  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 132  
aaggagctc gtcattccct g 21

<210> 133  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 133  
aacatcactg ttactttaaa a 21

<210> 134  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 134  
aaaaaagttt ccacttgaca c 21

<210> 135  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 135  
aaaaaagtttc cacttgacac t 21

<210> 136  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 136  
aaaagtttcc acttgacact t 21

<210> 137  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 137  
aaagtttcca cttgacactt t 21

<210> 138  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 138  
aagtttccac ttgacacttt g 21

<210> 139  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 139  
aaaacgcata atctgggaca g 21

<210> 140  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 140  
aaacgcataa tctgggacag t 21

<210> 141  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 141  
aacgcataat ctgggacagt a 21

<210> 142  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 142  
aatctgggac agtagaaagg g 21

<210> 143  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 143  
aaagggcttc atcatatcaa a 21

<210> 144  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 144  
aagggttca tcatatcaaa t 21

<210> 145  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 145  
aaatgcaacg tacaaagaaa t 21

<210> 146  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 146  
aatgcaacgt acaaagaaat a 21

<210> 147  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 147  
aacgtacaaa gaaatagggc t 21

<210> 148  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 148  
aaagaaatag ggcttctgac c 21

<210> 149  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 149  
aagaaatagg gcttctgacc t 21

<210> 150  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 150  
aaatagggct tctgacctgt g 21

<210> 151  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 151  
aatagggctt ctgacctgtg a 21

<210> 152  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 152

aagcaacagt caatgggcat t

21

<210> 153

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 153

aacagtcaat gggcatttgt a

21

<210> 154

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 154

aatgggcatt tgtataagac a

21

<210> 155

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 155

aagacaaact atctcacaca t

21

<210> 156

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 156

aaactatctc acacatcgac a

21

<210> 157

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 157

aactatctca cacatcgaca a

21

<210> 158

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 158  
aaaccaatac aatcatagat g 21

<210> 159  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 159  
aaccaatata atcatagatg t 21

<210> 160  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 160  
aatacaatca tagatgtcca a 21

<210> 161  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 161  
aatcatagat gtccaaataa g 21

<210> 162  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 162  
aaataagcac accacgccca g 21

<210> 163  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 163  
aataagcaca ccacgccag t 21

<210> 164  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 164  
aagcacacca cgcccagtca a 21

<210> 165  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 165  
aaattactta gaggccatac t 21

<210> 166  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 166  
aattacttag aggccatact c 21

<210> 167  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 167  
aattgtactg ctaccactcc c 21

<210> 168  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 168  
aacacgagag ttcaaattgac c 21

<210> 169  
<211> 21



<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 169  
aaatgacctg gagttaccct g 21

<210> 170  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 170  
aatgacctgg agttaccctg a 21

<210> 171  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 171  
aaaaaaataa gagagcttcc g 21

<210> 172  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 172  
aaaaaataag agagcttccg t 21

<210> 173  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 173  
aaaaataaga gagcttccgt a 21

<210> 174  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 174  
aaaataagag agcttccgta a 21

<210> 175  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 175  
aaataagaga gcttccgtaa g 21

<210> 176  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 176  
aataagagag cttccgtaag g 21

<210> 177  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 177  
aagagagctt ccgtaaggcg a 21

<210> 178  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 178  
aaggcgacga attgaccaa g 21

<210> 179  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 179  
aattgaccaa agcaattccc a 21

<210> 180  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 180

aaagcaattc ccatgccaac a

21

<210> 181

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 181

aagcaattcc catgccaaca t

21

<210> 182

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 182

aattcccatg ccaacatatt c

21

<210> 183

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 183

aacatattct acagtgttct t

21

<210> 184

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 184

aaaatgcaga acaaagacaa a

21

<210> 185

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 185

aatgcagaac aaagacaaag g 21

<210> 186  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 186  
aacaagaca aaggacttta t 21

<210> 187  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 187  
aaagacaaag gactttatac t 21

<210> 188  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 188  
aagacaaagg actttatact t 21

<210> 189  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 189  
aaaggacttt atactgtcg t 21

<210> 190  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 190  
aaggacttta tacttgtcgt g 21

<210> 191  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 191  
aaggagtgga ccatcattca a 21

<210> 192  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 192  
aaatctgtta acacctcagt g 21

<210> 193  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 193  
aatctgttaa cacctcagt c 21

<210> 194  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 194  
aacacctcag tgcatatata t 21

<210> 195  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 195  
aaagcattca tcactgtgaa a 21

<210> 196  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 196  
aagcattcat cactgtgaaa c 21

<210> 197  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 197  
aaacatcgaa aacagcaggt g 21

<210> 198  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 198  
aacatcgaaa acagcaggtg c 21

<210> 199  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 199  
aaaacagcag gtgcttgaaa c 21

<210> 200  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 200  
aaacagcagg tgcttgaaac c 21

<210> 201  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 201  
aacagcaggt gcttgaaacc g 21

<210> 202  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 202  
aaaccgtagc tggcaagcgg t 21

<210> 203  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 203  
aaccgtagct ggcaagcggc c 21

<210> 204  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 204  
aaccgtagct ggcaagcggc c 21

<210> 205  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 205  
aaagtgaagg catttcctc g 21

<210> 206  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 206  
aagtgaaggc atttcctcg c 21

<210> 207  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 207  
aaggcatttc cctcgccgga a 21

<210> 208  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 208  
aagttgtatg gttaaaagat g 21

<210> 209  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 209  
aaaagatggg ttacctgcga c 21

<210> 210  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 210  
aaagatgggt tacctgcgac t 21

<210> 211  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 211  
aagatgggtt acctgcgact g 21

<210> 212  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 212  
aaatctgctc gctatttgac t 21

<210> 213  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>



<223> Targeting sequence

<400> 213

aatctgctcg ctatttgact c

21

<210> 214

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 214

aattatcaag gacgtaactg a

21

<210> 215

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 215

aaggacgtaa ctgaagagga t

21

<210> 216

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 216

aactgaagag gatgcaggga a

21

<210> 217

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 217

aagaggatgc agggaattat a

21

<210> 218

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 218

aattatacaa tcttgctgag c

21

<210> 219

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 219  
aatcttgctg agcataaaac a 21

<210> 220  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 220  
aaaacagtca aatgtgttta a 21

<210> 221  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 221  
aaacagtcaa atgtgtttaa a 21

<210> 222  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 222  
aacagtcaaa tgtgtttaaa a 21

<210> 223  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 223  
aaatgtgttt aaaaacctca c 21

<210> 224  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 224  
aatgtgttta aaaacctcac t 21

<210> 225  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 225  
aaaaacctca ctgccactct a 21

<210> 226  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 226  
aaaacctcac tgccactcta a 21

<210> 227  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 227  
aaacctcact gccactctaa t 21

<210> 228  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 228  
aacctcactg ccactctaata t 21

<210> 229  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 229  
aattgtcaat gtgaaacccc a 21

<210> 230  
<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 230  
aatgtgaaac cccagattta c 21

<210> 231  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 231  
aaaccccaga ttacgaaaa g 21

<210> 232  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 232  
aaccccagat ttacgaaaag g 21

<210> 233  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 233  
aaaaggccgt gtcacgttt c 21

<210> 234  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 234  
aaaggccgtg tcacgtttc c 21

<210> 235  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 235  
aaggccgtgt catcgtttcc a 21

<210> 236  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 236  
aaatcctgac ttgtaccgca t 21

<210> 237  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 237  
aatcctgact tgtaccgcat a 21

<210> 238  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 238  
aacctacaat caagtggttc t 21

<210> 239  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 239  
aatcaagtgg ttctggcacc c 21

<210> 240  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 240  
aagtggttct ggcaccctg t 21

<210> 241  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 241

aaccataatc attccgaagc a

21

<210> 242

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 242

aatcattccg aagcaagggtg t

21

<210> 243

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 243

aagcaagggtg tgacttttgt t

21

<210> 244

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 244

aagggtgtgac ttttgttcca a

21

<210> 245

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 245

aataatgaag agtcctttat c

21

<210> 246

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 246

aatgaagagt cctttatcct g 21

<210> 247  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 247  
aagagtcctt ttcctggat g 21

<210> 248  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 248  
aacatgggaa acagaattga g 21

<210> 249  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 249  
aaacagaatt gagagcatca c 21

<210> 250  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 250  
aacagaattg agagcatcac t 21

<210> 251  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 251  
aattgagagc atcactcagc g 21

<210> 252  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 252  
aataatagaa ggaaagaata a 21

<210> 253  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 253  
aatagaagga aagaataaga t 21

<210> 254  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 254  
aaggaaagaa taagatggct a 21

<210> 255  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 255  
aaagaataag atggctagca c 21

<210> 256  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 256  
aagaataaga tggctagcac c 21

<210> 257  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 257  
aataagatgg ctagcacctt g 21



<210> 258  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 258  
aagatggcta gcaccttggt t 21

<210> 259  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 259  
aatttctgga atctacattt g 21

<210> 260  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 260  
aatctacatt tgcatagctt c 21

<210> 261  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 261  
aataaagttg ggactgtggg a 21

<210> 262  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 262  
aaagttggga ctgtgggaag a 21

<210> 263  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 263  
aagttgggac tgtggaaga a 21

<210> 264  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 264  
aagaaacata agcttttata t 21

<210> 265  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 265  
aaacataagc ttttatatca c 21

<210> 266  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 266  
aacataagct tttatatcac a 21

<210> 267  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 267  
aagcttttat atcacagatg t 21

<210> 268  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 268  
aaatgggttt catgttaact t 21

<210> 269  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 269  
aatgggtttc atgttaactt g 21

<210> 270  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 270  
aacttgga aaatgccgac g 21

<210> 271  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 271  
aaaaaatgcc gacggaagga g 21

<210> 272  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 272  
aaaaatgccg acggaaggag a 21

<210> 273  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 273  
aaaatgccga cggaaggaga g 21

<210> 274  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 274

aaatgccgac ggaaggagag g

21

<210> 275

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 275

aatgccgacg gaaggagagg a

21

<210> 276

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 276

aaggagagga cctgaaactg t

21

<210> 277

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 277

aaactgtctt gcacagttaa c

21

<210> 278

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 278

aactgtcttg cacagttaac a

21

<210> 279

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 279

aacaagttct tatacagaga c

21

<210> 280

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 280  
aagttcttat acagagacgt t 21

<210> 281  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 281  
aataacagaa caatgcacta c 21

<210> 282  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 282  
aacagaacaa tgcactacag t 21

<210> 283  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 283  
aacaatgcac tacagtatta g 21

<210> 284  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 284  
aatgcactac agtattagca a 21

<210> 285  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 285  
aagcaaaaaa tggccatcac t 21

<210> 286  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 286  
aaaaaatggc catcactaag g 21

<210> 287  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 287  
aaaaatggcc atcactaagg a 21

<210> 288  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 288  
aaaatggcca tcactaagga g 21

<210> 289  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 289  
aatggccat cactaaggag c 21

<210> 290  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 290  
aatggccatc actaaggagc a 21

<210> 291  
<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 291  
aaggagcact ccatactct t 21

<210> 292  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 292  
aatcttacca tcatgaatgt t 21

<210> 293  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 293  
aatgtttccc tgcaagattc a 21

<210> 294  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 294  
aagattcagg cacctatgcc t 21

<210> 295  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 295  
aatgtataca caggggaaga a 21

<210> 296  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 296  
aagaaatcct ccagaagaaa g 21

<210> 297  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 297  
aaatcctcca gaagaagaa a 21

<210> 298  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 298  
aatcctccag aagaagaaa t 21

<210> 299  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 299  
aagaagaaa ttacaatcag a 21

<210> 300  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 300  
aaagaaatta caatcagaga t 21

<210> 301  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 301  
aagaaattac aatcagagat c 21

<210> 302  
<211> 21  
<212> DNA



<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 302

aaattacaat cagagatcag g

21

<210> 303

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 303

aattacaatc agagatcagg a

21

<210> 304

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 304

aatcagagat caggaagcac c

21

<210> 305

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 305

aagcaccata cctcctgcga a

21

<210> 306

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 306

aaacctcagt gatcacacag t

21

<210> 307

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 307

aacctcagtg atcacacagt 20

<210> 308  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 308  
aatggtgtcc ccgagcctca g 21

<210> 309  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 309  
aaaaacaacc acaaaataca a 21

<210> 310  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 310  
aaaacaacca caaaatacaa c 21

<210> 311  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 311  
aaacaaccac aaaatacaac a 21

<210> 312  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 312  
aacaaccaca aaatacaaca a 21

<210> 313  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 313  
aaccacaaaa tacaacaaga g 21

<210> 314  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 314  
aaaatacaac aagagcctgg a 21

<210> 315  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 315  
aaatacaaca agagcctgga a 21

<210> 316  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 316  
aatacaacaa gagcctggaa t 21

<210> 317  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 317  
aacaagagcc tggaattatt t 21

<210> 318  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 318  
aagagcctgg aattatttta g 21

<210> 319  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 319  
aattatttta ggaccaggaa g 21

<210> 320  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 320  
aagcagcacg ctgtttattg a 21

<210> 321  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 321  
aaagagtcac agaagaggat g 21

<210> 322  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 322  
aagagtcaca gaagaggatg a 21

<210> 323  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 323  
aagaggatga aggtgtctat c 21

<210> 324  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 324  
aaggtgtcta tcactgcaaa g 21

<210> 325  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 325  
aaagccacca accagaaggg c 21

<210> 326  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 326  
aagccaccaa ccagaagggc t 21

<210> 327  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 327  
aaccagaagg gctctgtgga a 21

<210> 328  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 328  
aagggtctctg tggaaagttc a 21

<210> 329  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 329  
aaagttcagc atacctcact g 21

<210> 330  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 330  
aagttcagca tacctcactg t 21

<210> 331  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 331  
aaggaacctc ggacaagtct a 21

<210> 332  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 332  
aacctcggac aagtctaatac t 21

<210> 333  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 333  
aagtctaatac tggagctgat c 21

<210> 334  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 334  
aatctggagc tgatcactct a 21

<210> 335  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 335

aacatgcacc tgtgtggctg c

21

<210> 336

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 336

aaccctcttt atccgaaaaa t

21

<210> 337

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 337

aaaaatgaaa aggtcttctt c

21

<210> 338

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 338

aaaatgaaaa ggtcttcttc t

21

<210> 339

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 339

aaatgaaaag gtcttcttct g

21

<210> 340

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 340

aatgaaaagg tcttcttctg a

21

<210> 341

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 341  
aaaaggtcctt cttctgaaat a 21

<210> 342  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 342  
aaaggtcttc ttctgaaata a 21

<210> 343  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 343  
aaggtcttct tctgaaataa a 21

<210> 344  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 344  
aaataaagac tgactaccta t 21

<210> 345  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 345  
aataaagact gactacctat c 21

<210> 346  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence



<400> 346  
aaagactgac tacctatcaa t 21

<210> 347  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 347  
aagactgact acctatcaat t 21

<210> 348  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 348  
aattataatg gaccagatg a 21

<210> 349  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 349  
aatggacca gatgaagttc c 21

<210> 350  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 350  
aagttccttt ggatgagcag t 21

<210> 351  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 351  
aagtgggagt ttgccggga g 21

<210> 352  
<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 352  
aaactgggca aatcacttgg a 21

<210> 353  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 353  
aactgggcaa atcacttgga a 21

<210> 354  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 354  
aaatcacttg gaagaggggc t 21

<210> 355  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 355  
aatcacttgg aagaggggct t 21

<210> 356  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 356  
aagaggggct tttggaaaag t 21

<210> 357  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 357  
aaaagtggtt caagcatcag c 21

<210> 358  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 358  
aaagtgggtc aagcatcagc a 21

<210> 359  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 359  
aagtggttca agcatcagca t 21

<210> 360  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 360  
aagcatcagc atttggcatt a 21

<210> 361  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 361  
aagaaatcac ctacgtgccg g 21

<210> 362  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 362  
aatcaccta cgtgccggac t 21

<210> 363  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 363

aatcacctac gtgccggact g

21

<210> 364

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 364

aaaatgctga aagagggggc c

21

<210> 365

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 365

aaatgctgaa agagggggcc a

21

<210> 366

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 366

aatgctgaaa gagggggcca c

21

<210> 367

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 367

aaagaggggg ccacggccag c

21

<210> 368

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 368

aagagggggc cacggccagc g 21

<210> 369  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 369  
aaagctctga tgactgagct a 21

<210> 370  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 370  
aagctctgat gactgagcta a 21

<210> 371  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 371  
aaaaatcttg acccacattg g 21

<210> 372  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 372  
aaaatcttga ccacattgg c 21

<210> 373  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 373  
aaatcttgac ccacattggc c 21

<210> 374  
<211> 21  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 374

aatcttgacc cacattggcc a

21

&lt;210&gt; 375

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 375

aacgtgggta acctgctggg a

21

&lt;210&gt; 376

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 376

aacctgctgg gagcctgcac c

21

&lt;210&gt; 377

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 377

aagcaaggag ggcctctgat g

21

&lt;210&gt; 378

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 378

aaggagggcc tctgatggtg a

21

&lt;210&gt; 379

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 379

aatactgcaa atatggaaat c

21

<210> 380  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 380  
aaatatggaa atctctccaa c 21

<210> 381  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 381  
aatatggaaa tctctccaac t 21

<210> 382  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 382  
aaatctctcc aactacctca a 21

<210> 383  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 383  
aatctctcca actacctcaa g 21

<210> 384  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 384  
aactacctca agagcaaacg t 21

<210> 385  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 385  
aagagcaaac gtgacttatt t 21

<210> 386  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 386  
aaacgtgact tatTTTTTct c 21

<210> 387  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 387  
aacgtgactt atTTTTtctc a 21

<210> 388  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 388  
aacaaggatg cagcactaca c 21

<210> 389  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 389  
aaggatgcag cactacacat g 21

<210> 390  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 390  
aagaaagaaa aaatggagcc a 21



<210> 391  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 391  
aaagaaaaaa tggagccagg c 21

<210> 392  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 392  
aagaaaaaat ggagccaggc c 21

<210> 393  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 393  
aaaaaatgga gccaggcctg g 21

<210> 394  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 394  
aaaaatggag ccaggcctgg a 21

<210> 395  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 395  
aaaatggagc caggcctgga a 21

<210> 396  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 396

aaatggagcc aggcctggaa c

21

<210> 397

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 397

aatggagcca ggcctggaac a

21

<210> 398

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 398

aacaaggcaa gaaaccaaga c

21

<210> 399

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 399

aaggcaagaa accaagacta g

21

<210> 400

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 400

aagaaaccaa gactagatag c

21

<210> 401

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 401

aaaccaagac tagatagcgt c

21

<210> 402

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 402  
aaccaagact agatagcgtc a 21

<210> 403  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 403  
aagactagat agcgtcacca g 21

<210> 404  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 404  
aaagctttgc gagctccggc t 21

<210> 405  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 405  
aagctttgcg agctccggct 20

<210> 406  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 406  
aagataaaag tctgagtgat g 21

<210> 407  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 407  
aaaagtctga gtgatgttga g 21

<210> 408  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 408  
aaagtctgag tgatgttgag g 21

<210> 409  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 409  
aagtctgagt gatgttgagg a 21

<210> 410  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 410  
aagaggagga ttctgacggt t 21

<210> 411  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 411  
aaggagccca tcactatgga a 21

<210> 412  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 412  
aagatctgat ttcttacagt t 21

<210> 413  
<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 413  
aagtggccag aggcattgag t 21

<210> 414  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 414  
aaagtgcatt catcgggacc t 21

<210> 415  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 415  
aagtgcattc atcgggacct g 21

<210> 416  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 416  
aaacattctt ttatctgaga a 21

<210> 417  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 417  
aacattcttt tatctgagaa c 21

<210> 418  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 418  
aacaacgtgg tgaagatttg t 21

<210> 419  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 419  
aacgtggtga agatttgtga t 21

<210> 420  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 420  
aagatttgtg attttggcct t 21

<210> 421  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 421  
aagaaccccg attatgtgag a 21

<210> 422  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 422  
aaccgccgatt atgtgagaaa a 21

<210> 423  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 423  
aaaaggagat actcgacttc c 21

<210> 424  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 424

aaaggagata ctcgacttcc t

21

<210> 425

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 425

aaggagatac tcgacttcct c

21

<210> 426

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 426

aaatggatgg ctctgaatc t

21

<210> 427

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 427

aatggatggc tcctgaatct a

21

<210> 428

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 428

aatctatctt tgacaaaatc t

21

<210> 429

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 429

aaaatctaca gcaccaagag c 21

<210> 430  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 430  
aaatctacag caccaagagc g 21

<210> 431  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 431  
aatctacagc accaagagcg a 21

<210> 432  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 432  
aagagcgacg tgtggtctta c 21

<210> 433  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 433  
aaatcttctc cttaggtggg t 21

<210> 434  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 434  
aatcttctcc ttaggtgggt c 21

<210> 435  
<211> 21  
<212> DNA  
<213> Artificial Sequence



<220>  
<223> Targeting sequence

<400> 435  
aaatggatga ggacttttgc a 21

<210> 436  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 436  
aatggatgag gacttttgca g 21

<210> 437  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 437  
aaggcatgag gatgagagct c 21

<210> 438  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 438  
aaatctatca gatcatgctg g 21

<210> 439  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 439  
aatctatcag atcatgctgg a 21

<210> 440  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 440  
aaaagaaagg ccaagatttg c 21

<210> 441  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 441  
aaagaaaggc caagatttgc a 21

<210> 442  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 442  
aagaaaggcc aagatttgca g 21

<210> 443  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 443  
aaaggccaag atttgcagaa c 21

<210> 444  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 444  
aaggccaaga tttgcagaac t 21

<210> 445  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 445  
aagatttgca gaacttggtg a 21

<210> 446  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 446  
aacttggtga aaaactaggt g 21

<210> 447  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 447  
aaaaactagg tgatttgctt c 21

<210> 448  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 448  
aaaactaggt gatttgcttc a 21

<210> 449  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 449  
aaactagggtg atttgcttca a 21

<210> 450  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 450  
aactagggtga ttgcttcaa g 21

<210> 451  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 451  
aagcaaattgt acaacaggat g 21

<210> 452  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 452  
aaatgtacaa caggatggta a 21

<210> 453  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 453  
aatgtacaac aggatggtaa a 21

<210> 454  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 454  
aacaggatgg taaagactac a 21

<210> 455  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 455  
aaagactaca tccaatcaa t 21

<210> 456  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 456  
aagactacat cccaatcaat g 21

<210> 457  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 457

aatcaatgcc atactgacag g

21

<210> 458

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 458

aatgccatac tgacaggaaa t

21

<210> 459

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 459

aaatagtggg ttacatact c

21

<210> 460

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 460

aatagtgggt ttacatactc a

21

<210> 461

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 461

aactcctgcc ttctctgagg a

21

<210> 462

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 462

aaggaaagta tttcagctcc g

21

<210> 463

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 463  
aaagtatttc agctccgaag t 21

<210> 464  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 464  
aagtatttca gctccgaagt t 21

<210> 465  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 465  
aagtttaatt caggaagctc t 21

<210> 466  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 466  
aatcaggaa gctctgätga t 21

<210> 467  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 467  
aagctctgat gatgtcagat a 21

<210> 468  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 468  
aaatgctttc aagttcatga g 21

<210> 469  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 469  
aatgctttca agttcatgag c 21

<210> 470  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 470  
aagttcatga gcctggaaag a 21

<210> 471  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 471  
aaagaatcaa aacctttgaa g 21

<210> 472  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 472  
aagaatcaaa acctttgaag a 21

<210> 473  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 473  
aatcaaaacc ttgaagaac t 21

<210> 474  
<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 474  
aaaacctttg aagaactttt a 21

<210> 475  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 475  
aaacctttga agaactttta c 21

<210> 476  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 476  
aacctttgaa gaacttttac c 21

<210> 477  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 477  
aagaactttt accgaatgcc a 21

<210> 478  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 478  
aacttttacc gaatgccacc t 21

<210> 479  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence



<400> 479  
aatgccacct ccatgtttga t 21

<210> 480  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 480  
aaaccaagg cctcgctcaa g 21

<210> 481  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 481  
aaaccaagg cctcgctcaa g 21

<210> 482  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 482  
aaccaaggc ctcgctcaag a 21

<210> 483  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 483  
aaggcctcgc tcaagattga c 21

<210> 484  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 484  
aagattgact tgagagtaac c 21

<210> 485  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 485

aaccagtaaa agtaaggagt c

21

<210> 486

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 486

aaaagtaagg agtcggggct g

21

<210> 487

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 487

aaagtaagga gtcggggctg t

21

<210> 488

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 488

aagtaaggag tcggggctgt c

21

<210> 489

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 489

aaggagtcgg ggctgtctga t

21

<210> 490

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 490

aaggcaagcg caggttcacc t 21

<210> 491  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 491  
gcacccagca catcatgcaa g 21

<210> 492  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 492  
ggctgagcat aactaaatct g 21

<210> 493  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 493  
gcttctacag ctgcaaatat c 21

<210> 494  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 494  
gagctcgtca ttccctgccg g 21

<210> 495  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 495  
ccaaagcaat tcccatgcc a 21

<210> 496  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 496  
tgctgagcat aaaacagtca a 21

<210> 497  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 497  
ttgcatagct tccaataaag t 21

<210> 498  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 498  
agtgatcaca cagtggccat c 21

<210> 499  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 499  
gatgaagttc ctttgatga g 21

<210> 500  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 500  
tacacatgga gcctaagaaa g 21

<210> 501  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 501  
gagctccggc tttcaggaag a 21

<210> 502  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 502  
tctacagcac caagagcgac g 21

<210> 503  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 503  
tctgatgatg tcagatatgt a 21

<210> 504  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 504  
gcctcgctca agattgactt g 21

<210> 505  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 505  
aaaaagacat acttacaatt a 21

<210> 506  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 506  
aaaagacata cttacaatta a 21

<210> 507  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 507  
aaagacatac ttacaattaa g 21

<210> 508  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 508  
aagacatact tacaattaag g 21

<210> 509  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 509  
aattaaggct aatacaactc t 21

<210> 510  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 510  
aaggctaata caactcttca a 21

<210> 511  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 511  
aatacaactc ttcaaattac t 21

<210> 512  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 512  
aactcttcaa attacttgca g 21

<210> 513  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 513  
aaattacttg caggggacag a 21

<210> 514  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 514  
aattacttgc aggggacaga g 21

<210> 515  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 515  
aataatcaga gtggcagtga g 21

<210> 516  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 516  
aatcagagtg gcagtgagca a 21

<210> 517  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 517  
aaagggtgga ggtgactgag t 21

<210> 518  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 518

aagggtggag gtgactgagt g

21

<210> 519

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 519

aagacactca caattccaaa a

21

<210> 520

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 520

aattccaaaa gtgatcggaa a

21

<210> 521

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 521

aaaagtgatc ggaaatgaca c

21

<210> 522

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 522

aaagtgatcg gaaatgacac t

21

<210> 523

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 523

aagtgatcgg aaatgacact g

21

<210> 524



<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 524  
aatgacact ggagcctaca a 21

<210> 525  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 525  
aatgacactg gaggcctacaa g 21

<210> 526  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 526  
aagtgccttct accgggaaac t 21

<210> 527  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 527  
aaactgactt ggcctcggtc a 21

<210> 528  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 528  
aactgacttg gcctcgggtca t 21

<210> 529  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 529  
aagattacag atctccattt a 21  
  
<210> 530  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Targeting sequence  
  
<400> 530  
aacatggagt cgtgtacatt a 21  
  
<210> 531  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Targeting sequence  
  
<400> 531  
aacaaaaaca aaactgtggt g 21  
  
<210> 532  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Targeting sequence  
  
<400> 532  
aaaaacaaaa ctgtggtgat t 21  
  
<210> 533  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Targeting sequence  
  
<400> 533  
aaaacaaaac tgtggtgatt c 21  
  
<210> 534  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Targeting sequence  
  
<400> 534  
aaacaaaact gtggtgattc c 21  
  
<210> 535  
<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 535  
aacaaaactg tggtgattcc a 21

<210> 536  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 536  
aaaactgtgg tgattccatg t 21

<210> 537  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 537  
aaactgtggt gattccatgt c 21

<210> 538  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 538  
aactgtgggt attccatgtc t 21

<210> 539  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 539  
aaatctcaac gtgtcacttt g 21

<210> 540  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 540  
aatctcaacg tgtcactttg t 21

<210> 541  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 541  
aacgtgtcac tttgtgcaag a 21

<210> 542  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 542  
aagataccca gaaaagagat t 21

<210> 543  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 543  
aaaagagatt tgttcctgat g 21

<210> 544  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 544  
aaagagattt gttcctgatg g 21

<210> 545  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 545  
aagagatttg ttcctgatgg t 21

<210> 546  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 546

aacagaattt cctgggacag c

21

<210> 547

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 547

aatttcctgg gacagcaaga a

21

<210> 548

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 548

aagaagggtt ttactattcc c

21

<210> 549

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 549

aagggttcta ctattcccag c

21

<210> 550

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 550

aagcaaaaat taatgatgaa a

21

<210> 551

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 551

aaaaattaat gatgaaagtt a 21

<210> 552  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 552  
aaaattaatg atgaaagtta c 21

<210> 553  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 553  
aaattaatga tgaaagttac c 21

<210> 554  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 554  
aattaatgat gaaagttacc a 21

<210> 555  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 555  
aatgatgaaa gttaccagtc t 21

<210> 556  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 556  
aaagttacca gtctattatg t 21

<210> 557  
<211> 21  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 557

aagttaccag tctattatgt a

21

&lt;210&gt; 558

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 558

aattgaacta tctgttgag a

21

&lt;210&gt; 559

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 559

aactatctgt tggagaaaag c

21

&lt;210&gt; 560

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 560

aaaagcttgt cttaaattgt a

21

&lt;210&gt; 561

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 561

aaagcttgct ttaaattgta c

21

&lt;210&gt; 562

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 562

aagcttgct taaattgtac a

21

<210> 563  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 563  
aaattgtaca gcaagaactg a 21

<210> 564  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 564  
aattgtacag caagaactga a 21

<210> 565  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 565  
aagaactgaa ctaaattgtgg g 21

<210> 566  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 566  
aactgaacta aatgtgggga t 21

<210> 567  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 567  
aactaaatgt ggggattgac t 21

<210> 568  
<211> 21  
<212> DNA  
<213> Artificial Sequence



<220>  
<223> Targeting sequence

<400> 568  
aaatgtgggg attgacttca a 21

<210> 569  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 569  
aatgtgggga ttgacttcaa c 21

<210> 570  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 570  
aactgggaat acccttcttc g 21

<210> 571  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 571  
aatacccttc ttcgaagcat c 21

<210> 572  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 572  
aagcatcagc ataagaaact t 21

<210> 573  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 573  
aagaaacttg taaaccgaga c 21

<210> 574  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 574  
aaacttgtaa accgagacct a 21

<210> 575  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 575  
aacttgtaaa ccgagacct a 21

<210> 576  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 576  
aaaccgagac ctaaaaaccc a 21

<210> 577  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 577  
aaccgagacc taaaaaccca g 21

<210> 578  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 578  
aaaaaccag tctgggagt g 21

<210> 579  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 579

aaaaccagtg ctgggagtga g

21

<210> 580

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 580

aaaccagtc tgggagtga a

21

<210> 581

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 581

aaccagtc tgggagtga t

21

<210> 582

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 582

aagaaatttt tgagcacctt a

21

<210> 583

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 583

aaatttttga gcaccttaac t

21

<210> 584

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 584

aatttttgag caccttaact a

21

<210> 585

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 585  
aactatagat ggtgtaaccc g 21

<210> 586  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 586  
aaccggagt gaccaaggat t 21

<210> 587  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 587  
aaggattgta cacctgtgca g 21

<210> 588  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 588  
aagaagaaca gcacatttgt c 21

<210> 589  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 589  
aagaacagca catttgtcag g 21

<210> 590  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 590  
aacagcacat ttgtcagggt c 21

<210> 591  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 591  
aaaaaccttt tgttgctttt g 21

<210> 592  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 592  
aaaacctttt gttgcttttg g 21

<210> 593  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 593  
aaaccttttg ttgcttttgg a 21

<210> 594  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 594  
aaccttttgt tgcttttgga a 21

<210> 595  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 595  
aagtggcatg gaatctctgg t 21

<210> 596  
<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 596  
aatctctggt ggaagccacg g 21

<210> 597  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 597  
aagccacggt gggggagcgt g 21

<210> 598  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 598  
aatccctgcg aagtaccttg g 21

<210> 599  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 599  
aagtaccttg gttaccacc c 21

<210> 600  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 600  
aaataaaatg gtataaaaat g 21

<210> 601  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 601  
aataaaatgg tataaaaatg g 21

<210> 602  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 602  
aaaatggtat aaaaatggaa t 21

<210> 603  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 603  
aaatggtata aaaatggaat a 21

<210> 604  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 604  
aatggtataa aaatggaata c 21

<210> 605  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 605  
aaaaatggaa tacccttga g 21

<210> 606  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 606  
aaaatggaat accccttgag t 21

<210> 607  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 607

aaatggaata ccccttgagt c

21

<210> 608

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 608

aatggaatac cccttgagtc c

21

<210> 609

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 609

aatacccctt gagtccaatc a

21

<210> 610

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 610

aatcacacaa ttaaagcggg g

21

<210> 611

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 611

aattaaagcg gggcatgtac t

21

<210> 612

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 612



aaagcggggc atgtactgac g 21

<210> 613  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 613  
aagcggggca tgtactgacg a 21

<210> 614  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 614  
aagtgagtga aagagacaca g 21

<210> 615  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 615  
aaagagacac aggaaattac a 21

<210> 616  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 616  
aagagacaca ggaaattaca c 21

<210> 617  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 617  
aaattacact gtcacotta c 21

<210> 618  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 618  
aattacactg tcatccttac c 21

<210> 619  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 619  
aatcccatTTT caaaggagaa g 21

<210> 620  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 620  
aaaggagaag cagagccatg t 21

<210> 621  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 621  
aaggagaagc agagccatgt g 21

<210> 622  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 622  
aagcagagcc atgtggtctc t 21

<210> 623  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 623  
aaatctctaa tctctcctgt g 21

<210> 624  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 624  
aatctctaatt ctctcctgtg g 21

<210> 625  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 625  
aatctctcct gtggattcct a 21

<210> 626  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 626  
aaacgctgac atgtacggtc t 21

<210> 627  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 627  
aacgctgaca tgtacggtct a 21

<210> 628  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 628  
aagagtgcgc caacgagccc a 21

<210> 629  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 629  
aacgagccca gccaaagtgt c 21

<210> 630  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 630  
aagctgtctc agtgacaaac c 21

<210> 631  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 631  
aaacccatac ccttgtgaag a 21

<210> 632  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 632  
aaccatacc ctttgtgaaga a 21

<210> 633  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 633  
aagaatggag aagtgtggag g 21

<210> 634  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 634  
aatggagaag tgtggaggac t 21

<210> 635  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 635  
aagtgtggag gacttccagg g 21

<210> 636  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 636  
aaataaaaatt gaagttaata a 21

<210> 637  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 637  
aataaaaattg aagttaataa a 21

<210> 638  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 638  
aaaattgaag ttaataaaaa t 21

<210> 639  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 639  
aaattgaagt taataaaaat c 21

<210> 640  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 640

aattgaagtt aataaaaatc a

21

<210> 641

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 641

aagttaataa aaatcaattt g

21

<210> 642

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 642

aataaaaatc aatttgctct a

21

<210> 643

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 643

aaaaatcaat ttgctctaatt t

21

<210> 644

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 644

aaaatcaatt tgctctaatt g

21

<210> 645

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 645

aaatcaattt gctctaattg a

21

<210> 646

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 646  
aatcaatttg ctctaattga a 21

<210> 647  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 647  
aatttgctct aattgaagga a 21

<210> 648  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 648  
aattgaagga aaaaacaaaa c 21

<210> 649  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 649  
aaggaaaaaa caaaactgta a 21

<210> 650  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 650  
aaaaaacaaa actgtaagta c 21

<210> 651  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 651  
aaaaacaaaa ctgtaagtac c 21

<210> 652  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 652  
aaaacaaaac tgtaagtacc c 21

<210> 653  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 653  
aaacaaaact gtaagtaccc t 21

<210> 654  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 654  
aacaaaactg taagtaccct t 21

<210> 655  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 655  
aaaactgtaa gtacccttgt t 21

<210> 656  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 656  
aaactgtaag tacccttggt a 21

<210> 657  
<211> 21



<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 657  
aactgtaagt acccttgta t 21

<210> 658  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 658  
aagtaccctt gttatccaag c 21

<210> 659  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 659  
aagcggcaaa tgtgtcagct t 21

<210> 660  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 660  
aaatgtgtca gctttgtaca a 21

<210> 661  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 661  
aatgtgtcag ctttgtacaa a 21

<210> 662  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 662  
aaatgtgaag cggtaacaa a 21

<210> 663  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 663  
aatgtgaagc ggtcaacaaa g 21

<210> 664  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 664  
aagcgggtcaa caagtcggg a 21

<210> 665  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 665  
aacaaagtcg ggagaggaga g 21

<210> 666  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 666  
aaagtcggga gaggagagag g 21

<210> 667  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 667  
aagtcgggag aggagagagg g 21

<210> 668  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 668

aaattacttt gcaacctgac a

21

<210> 669

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 669

aattactttg caacctgaca t

21

<210> 670

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 670

aacctgacat gcagcccact g

21

<210> 671

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 671

aacctcacat ggtacaagct t

21

<210> 672

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 672

aagcttggcc cacagcctct g

21

<210> 673

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 673

aatccatgtg ggagagttgc c 21

<210> 674  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 674  
aagaacttgg atactctttg g 21

<210> 675  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 675  
aacttgata ctctttggaa a 21

<210> 676  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 676  
aaattgaatg ccacatggt c 21

<210> 677  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 677  
aattgaatgc caccatgttc t 21

<210> 678  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 678  
aatgccacca tgttctctaa t 21

<210> 679  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 679  
aatagcacao atgacatttt g 21

<210> 680  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 680  
aatgacatt ttgatcatgg a 21

<210> 681  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 681  
aatgacattt tgatcatgga g 21

<210> 682  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 682  
aagaatgcat ccttgacagga c 21

<210> 683  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 683  
aatgcatcct tgcaggacca a 21

<210> 684  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 684  
aaggagacta tgtctgcctt g 21

<210> 685  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 685  
aagacaggaa gaccaagaaa a 21

<210> 686  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 686  
aagaccaaga aaagacattg c 21

<210> 687  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 687  
aagaaaagac attgcgtggt c 21

<210> 688  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 688  
aaaagacatt gcgtggtcag g 21

<210> 689  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 689  
aaagacattg cgtggtcagg c 21

<210> 690  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 690  
aagacattgc gtggtcaggc a 21

<210> 691  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 691  
aaacctggag aatcagacga c 21

<210> 692  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 692  
aacctggaga atcagacgac a 21

<210> 693  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 693  
aatcagacga caagtattgg g 21

<210> 694  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 694  
aagtattggg gaaagcatcg a 21

<210> 695  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 695  
aaagcatcga agtctcatgc a 21

<210> 696  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 696  
aagcatcgaa gtctcatgca c 21

<210> 697  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 697  
aatccccctc cacagatcat g 21

<210> 698  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 698  
aaagataatg agacccttgt a 21

<210> 699  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 699  
aagataatga gacccttgta g 21

<210> 700  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 700  
aatgagaccc ttgtagaaga c 21

<210> 701  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>



<223> Targeting sequence

<400> 701

aagactcagg cattgtattg a

21

<210> 702

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 702

aaggatggga accggaacct c

21

<210> 703

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 703

aaccggaacc tcactatccg c

21

<210> 704

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 704

aacctcacta tccgcagagt g

21

<210> 705

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 705

aaggaggacg aaggcctcta c

21

<210> 706

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 706

aaggcctcta cacctgccag g

21

<210> 707

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 707  
aaaagtggag gcatttttca t 21

<210> 708  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 708  
aaagtggagg catttttcat a 21

<210> 709  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 709  
aagtggaggc atttttcata a 21

<210> 710  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 710  
aatagaaggt gcccaggaaa a 21

<210> 711  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 711  
aaggtgccca ggaaaagacg a 21

<210> 712  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 712  
aaaagacgaa cttggaaatc a 21

<210> 713  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 713  
aaagacgaac ttggaaatca t 21

<210> 714  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 714  
aagacgaact tggaaatcat t 21

<210> 715  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 715  
aacttggaatc tcattattct a 21

<210> 716  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 716  
aatcattat tctagtaggc a 21

<210> 717  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 717  
aatcattatt ctagtaggca c 21

<210> 718  
<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 718  
aagcggggcca atggagggga a 21

<210> 719  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 719  
aatggagggg aactgaagac a 21

<210> 720  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 720  
aactgaagac aggctacttg t 21

<210> 721  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 721  
aagacaggct acttgtccat c 21

<210> 722  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 722  
aactcccatt ggatgaacat t 21

<210> 723  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 723  
aacattgtga acgactgcct t 21

<210> 724  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 724  
aacgactgcc ttatgatgcc a 21

<210> 725  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 725  
aaatgggaat tccccagaga c 21

<210> 726  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 726  
aatgggaatt ccccagagac c 21

<210> 727  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 727  
aattccccag agaccgctg a 21

<210> 728  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 728  
aagctaggta agcctcttgg c 21

<210> 729  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 729

aagcctcttg gccgtggtgc c

21

<210> 730

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 730

aagtgattga agcagatgcc t

21

<210> 731

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 731

aagcagatgc ctttgaatt g

21

<210> 732

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 732

aattgacaag acagcaactt g

21

<210> 733

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 733

aagacagcaa cttgcaggac a

21

<210> 734

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 734

aacttgccagg acagtagcag t

21

<210> 735

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 735

aaaatgttga aagaaggagc a

21

<210> 736

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 736

aaatgttgaa agaaggagca a

21

<210> 737

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 737

aatgttgaaa gaaggagcaa c

21

<210> 738

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 738

aaagaaggag caacacacag t

21

<210> 739

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 739

aagaaggagc aacacacagt g

21

<210> 740

<211> 21

<212> DNA

<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 740  
aaggagcaac acacagtgag c 21

<210> 741  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 741  
aacacacagt gagcatcgag c 21

<210> 742  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 742  
aactcaagat cctcattcat a 21

<210> 743  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 743  
aagatcctca ttcatattgg t 21

<210> 744  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 744  
aatgtggtca accttctagg t 21

<210> 745  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 745  
aaccttctag gtgcctgtac c 21



}  
<210> 746  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Targeting sequence  
  
<400> 746  
aagccaggag ggccactcat g 21  
  
<210> 747  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Targeting sequence  
  
<400> 747  
aattctgcaa atttggaac c 21  
  
<210> 748  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Targeting sequence  
  
<400> 748  
aaatttgga acctgtccac t 21  
  
<210> 749  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Targeting sequence  
  
<400> 749  
aatttggaaa cctgtccact t 21  
  
<210> 750  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Targeting sequence  
  
<400> 750  
aaacctgtcc acttacctga g 21  
  
<210> 751  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 751  
aacctgtcca cttacctgag g 21

<210> 752  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 752  
aagagaaatg aatttgtccc c 21

<210> 753  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 753  
aaatgaattt gtcccctaca a 21

<210> 754  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 754  
aatgaatttg tcccctacaa g 21

<210> 755  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 755  
aatttgtccc ctacaagacc a 21

<210> 756  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 756  
aagaccaaag gggcacgatt c 21

<210> 757  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 757  
aaaggggcac gattccgtca a 21

<210> 758  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 758  
aaggggcacg attccgtcaa g 21

<210> 759  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 759  
aagggaaaga ctacgttgga g 21

<210> 760  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 760  
aaagactacg ttggagcaat c 21

<210> 761  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 761  
aagactacgt ttggagcaatc c 21

<210> 762  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 762

aatccctgtg gatctgaaac g

21

<210> 763

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 763

aaacggcgct tggacagcat c

21

<210> 764

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 764

aacggcgctt ggacagcatc a

21

<210> 765

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 765

aagtcctca gtgatgtaga a

21

<210> 766

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 766

aagaagagga agctcctgaa g

21

<210> 767

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 767

aagaggaagc tcctgaagat c

21

<210> 768

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 768  
aagctcctga agatctgtat a 21

<210> 769  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 769  
aagatctgta taaggacttc c 21

<210> 770  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 770  
aaggacttcc tgaccttgga g 21

<210> 771  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 771  
aagtggctaa gggcatggag t 21

<210> 772  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 772  
aagggcatgg agttcttggc a 21

<210> 773  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 773  
aaagtgtatc cacagggacc t 21

<210> 774  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 774  
aagtgtatcc acagggacct g 21

<210> 775  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 775  
aaatatcctc ttatcggaga a 21

<210> 776  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 776  
aatatcctct tatcggagaa g 21

<210> 777  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 777  
aatatcctct tatcggagaa g 21

<210> 778  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 778  
aagaacgtgg ttaaaatctg t 21

<210> 779  
<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 779  
aacgtggtta aaatctgtga c 21

<210> 780  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 780  
aaaatctgtg actttggctt g 21

<210> 781  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 781  
aaatctgtga ctttggcttg g 21

<210> 782  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 782  
aatctgtgac tttggcttgg c 21

<210> 783  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 783  
aaagatccag attatgtcag a 21

<210> 784  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 784  
aagatccaga ttatgtcaga a 21

<210> 785  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 785  
aaaaggagat gctcgctcc c 21

<210> 786  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 786  
aaaggagatg ctgcctccc t 21

<210> 787  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 787  
aaggagatgc tcgcctccct t 21

<210> 788  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 788  
aaatggatgg cccagaaac a 21

<210> 789  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 789  
aatggatggc cccagaaaca a 21

<210> 790  
<211> 21  
<212> DNA



<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 790

aaacaatttt tgacagagtg t

21

<210> 791

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 791

aaacaattttt gacagagtgt a

21

<210> 792

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 792

aatttttgac agagtgtaca c

21

<210> 793

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 793

aatccagagt gacgtctggt c

21

<210> 794

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 794

aaatattttc cttaggtgct t

21

<210> 795

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 795

aatattttcc ttaggtgctt c 21

<210> 796  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 796  
aaagattgat gaagaatttt g 21

<210> 797  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 797  
aagattgatg aagaattttg t 21

<210> 798  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 798  
aagaattttg taggcgattg a 21

<210> 799  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 799  
aattttgtag gcgattgaaa g 21

<210> 800  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 800  
aaagaaggaa ctagaatgag g 21

<210> 801  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 801  
aagaaggaac tagaatgagg g 21

<210> 802  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 802  
aaggaactag aatgagggcc c 21

<210> 803  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 803  
aactagaatg agggcccctg a 21

<210> 804  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 804  
aatgagggcc cctgattata c 21

<210> 805  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 805  
aaatgtacca gaccatgctg g 21

<210> 806  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 806  
aatgtaccag accatgctgg a 21

<210> 807  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 807  
aacatttggg aaatctcttg c 21

<210> 808  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 808  
aaatctcttg caagctaag c 21

<210> 809  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 809  
aatctcttgc aagctaagc t 21

<210> 810  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 810  
aagctaagc tcagcaggat g 21

<210> 811  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 811  
aatgctcagc aggatggcaa a 21

<210> 812  
<211> 21  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 812

aaagactaca ttgttcttcc g

21

&lt;210&gt; 813

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 813

aagactacat tgttcttccg a

21

&lt;210&gt; 814

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 814

aagaggattc tggactctct c

21

&lt;210&gt; 815

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 815

aagtatgtga ccccaaattc c

21

&lt;210&gt; 816

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 816

aaattccatt atgacaacac a

21

&lt;210&gt; 817

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 817

aattccatta tgacaacaca g

21

<210> 818  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 818  
aacacagcag gaatcagtca g 21

<210> 819  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 819  
aatcagtcag tatctgcaga a 21

<210> 820  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 820  
aacagtaagc gaaagagccg g 21

<210> 821  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 821  
aagcgaaaga gccggcctgt g 21

<210> 822  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 822  
aaagagccgg cctgtgagt g t 21

<210> 823  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 823  
aagagccggc ctgtgagtgt a 21

<210> 824  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 824  
aaaaacattt gaagatatcc c 21

<210> 825  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 825  
aaaacatttg aagatatccc g 21

<210> 826  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 826  
aaacatttga agatatcccg t 21

<210> 827  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 827  
aacatttgaa gatatcccg t 21

<210> 828  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 828  
aagatatccc gttagaagaa c 21

<210> 829

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 829  
aagaaccaga agtaaaagta a 21

<210> 830  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 830  
aaccagaagt aaaagtaatc c 21

<210> 831  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 831  
aagtaaaagt aatcccagat g 21

<210> 832  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 832  
aaaagtaatc ccagatgaca a 21

<210> 833  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 833  
aaagtaatcc cagatgacaa c 21

<210> 834  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence



<400> 834  
aagtaatccc agatgacaac c 21

<210> 835  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 835  
aatcccagat gacaaccaga c 21

<210> 836  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 836  
aaccagacgg acagtggat g 21

<210> 837  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 837  
aagagctgaa aactttggaa g 21

<210> 838  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 838  
aaaactttgg aagacagaac c 21

<210> 839  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 839  
aaactttgga agacagaacc a 21

<210> 840  
<211> 21

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 840  
aactttggaa gacagaacca a 21

<210> 841  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 841  
aagacagaac caaattatct c 21

<210> 842  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 842  
aaccaaatta tctccatctt t 21

<210> 843  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 843  
aaattatctc catcttttgg t 21

<210> 844  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 844  
aattatctcc atcttttgg t 21

<210> 845  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 845  
aatggtgccc agcaaaagca g 21

<210> 846  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 846  
aaaagcaggg agtctgtggc a 21

<210> 847  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 847  
aaagcagggg gtctgtggca t 21

<210> 848  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 848  
aagcaggggag tctgtggcat c 21

<210> 849  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 849  
aaggctcaaa ccagacaagc g 21

<210> 850  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 850  
aaaccagaca agcggctacc a 21

<210> 851  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 851

aaccagacaa gcggctacca g

21

<210> 852

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 852

aagcggctac cagtccggat a

21

<210> 853

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 853

aagcagaact tttaaagctg a

21

<210> 854

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 854

gacatactta caattaaggc t

21

<210> 855

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 855

gatttggtcc tgatggtaac a

21

<210> 856

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Targeting sequence

<400> 856

ttttgagcac cttaactata g 21

<210> 857  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 857  
gagccatgtg gtctctctgg t 21

<210> 858  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 858  
ggtgatctcc ttccacgtga c 21

<210> 859  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 859  
gtggtcaggc agctcacagt c 21

<210> 860  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 860  
cggtgattgc catgttcttc t 21

<210> 861  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Targeting sequence

<400> 861  
ttctaggtgc ctgtaccaag c 21

<210> 862  
<211> 21  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 862

tgtatccaca gggacctggc g

21

&lt;210&gt; 863

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 863

taccagacca tgctggactg c

21

&lt;210&gt; 864

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Targeting sequence

&lt;400&gt; 864

ttatctccat cttttggtgg a

21